Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,25829395,time from sugammadex to recovery to train-of-four (T4/T1) ratio,Primary efficacy variable was time from sugammadex to recovery to train-of-four (T4/T1) ratio 0.9.,"Efficacy, safety and pharmacokinetics of sugammadex 4 mg kg-1 for reversal of deep neuromuscular blockade in patients with severe renal impairment. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25829395/),,0.9,449,DB00728,Rocuronium
,25829395,time from sugammadex to recovery to T4/T1 ratio 0.9,Median (95% CI) time from sugammadex to recovery to T4/T1 ratio 0.9 was 3.1 (2.4-4.6) and 1.9 (1.6-2.8) min for renal patients vs controls.,"Efficacy, safety and pharmacokinetics of sugammadex 4 mg kg-1 for reversal of deep neuromuscular blockade in patients with severe renal impairment. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25829395/),min,3.1,450,DB00728,Rocuronium
,25829395,time from sugammadex to recovery to T4/T1 ratio 0.9,Median (95% CI) time from sugammadex to recovery to T4/T1 ratio 0.9 was 3.1 (2.4-4.6) and 1.9 (1.6-2.8) min for renal patients vs controls.,"Efficacy, safety and pharmacokinetics of sugammadex 4 mg kg-1 for reversal of deep neuromuscular blockade in patients with severe renal impairment. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25829395/),min,1.9,451,DB00728,Rocuronium
≥,31572990,time to TOF,"With a TOF Watch SX device, the time to TOF ≥0.9 was recorded.","Effect of Concurrent Lidocaine, Remifentanil and Methylprednisolone Use on the Clinical Effect of Sugammadex under General Anaesthesia in Rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31572990/),,0.9,3123,DB00728,Rocuronium
≥,31572990,time to TOF,"However, in Group 2, time to TOF ≥0.9 was prolonged significantly when compared with the control group.","Effect of Concurrent Lidocaine, Remifentanil and Methylprednisolone Use on the Clinical Effect of Sugammadex under General Anaesthesia in Rats. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31572990/),,0.9,3124,DB00728,Rocuronium
,19156973,Vc,"The pharmacokinetics of rocuronium in DMD patients were Vc 63 +/- 14 ml kg(-1), Cl 3.0 +/- 1.0 ml min(-1) kg(-1), half-lives 2.0 +/- 0.6, 20 +/- 10 and 129 +/- 98 min, SE.",Pharmacodynamic modelling of rocuronium in adolescents with Duchenne muscular dystrophy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19156973/),[ml] / [kg],63,4924,DB00728,Rocuronium
,19156973,Cl,"The pharmacokinetics of rocuronium in DMD patients were Vc 63 +/- 14 ml kg(-1), Cl 3.0 +/- 1.0 ml min(-1) kg(-1), half-lives 2.0 +/- 0.6, 20 +/- 10 and 129 +/- 98 min, SE.",Pharmacodynamic modelling of rocuronium in adolescents with Duchenne muscular dystrophy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19156973/),[ml] / [kg·min],3.0,4925,DB00728,Rocuronium
,19156973,half-lives,"The pharmacokinetics of rocuronium in DMD patients were Vc 63 +/- 14 ml kg(-1), Cl 3.0 +/- 1.0 ml min(-1) kg(-1), half-lives 2.0 +/- 0.6, 20 +/- 10 and 129 +/- 98 min, SE.",Pharmacodynamic modelling of rocuronium in adolescents with Duchenne muscular dystrophy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19156973/),min,2.0,4926,DB00728,Rocuronium
,19156973,half-lives,"The pharmacokinetics of rocuronium in DMD patients were Vc 63 +/- 14 ml kg(-1), Cl 3.0 +/- 1.0 ml min(-1) kg(-1), half-lives 2.0 +/- 0.6, 20 +/- 10 and 129 +/- 98 min, SE.",Pharmacodynamic modelling of rocuronium in adolescents with Duchenne muscular dystrophy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19156973/),min,20,4927,DB00728,Rocuronium
,19156973,half-lives,"The pharmacokinetics of rocuronium in DMD patients were Vc 63 +/- 14 ml kg(-1), Cl 3.0 +/- 1.0 ml min(-1) kg(-1), half-lives 2.0 +/- 0.6, 20 +/- 10 and 129 +/- 98 min, SE.",Pharmacodynamic modelling of rocuronium in adolescents with Duchenne muscular dystrophy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19156973/),min,129,4928,DB00728,Rocuronium
,19156973,T(1/2)ke0,"In patients with DMD, the equilibration between the central and effect compartment was significantly slower (T(1/2)ke0: 9.7 +/- 0.3 vs. 1.3 +/- 0.1 min) and the EC(50) was significantly smaller (512 +/- 20 vs.",Pharmacodynamic modelling of rocuronium in adolescents with Duchenne muscular dystrophy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19156973/),min,9.7,4929,DB00728,Rocuronium
,19156973,T(1/2)ke0,"In patients with DMD, the equilibration between the central and effect compartment was significantly slower (T(1/2)ke0: 9.7 +/- 0.3 vs. 1.3 +/- 0.1 min) and the EC(50) was significantly smaller (512 +/- 20 vs.",Pharmacodynamic modelling of rocuronium in adolescents with Duchenne muscular dystrophy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19156973/),min,1.3,4930,DB00728,Rocuronium
,19156973,EC(50),"In patients with DMD, the equilibration between the central and effect compartment was significantly slower (T(1/2)ke0: 9.7 +/- 0.3 vs. 1.3 +/- 0.1 min) and the EC(50) was significantly smaller (512 +/- 20 vs.",Pharmacodynamic modelling of rocuronium in adolescents with Duchenne muscular dystrophy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19156973/),,512,4931,DB00728,Rocuronium
,19156973,ED(50),"1170 +/- 64 ng ml(-1)), whereas the ED(50) was 0.16 +/- 0.02 mg kg(-1) in both groups.",Pharmacodynamic modelling of rocuronium in adolescents with Duchenne muscular dystrophy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19156973/),[mg] / [kg],0.16,4932,DB00728,Rocuronium
,30924939,recovery,"Mean recovery from plasma was 91-93% for propofol, 89-93% for ketamine and 90-92% for rocuronium.","Simultaneous quantification of propofol, ketamine and rocuronium in just 10 μL plasma using liquid chromatography coupled with quadrupole mass spectrometry and its pilot application to a pharmacokinetic study in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30924939/),%,91-93,12804,DB00728,Rocuronium
,30924939,recovery,"Mean recovery from plasma was 91-93% for propofol, 89-93% for ketamine and 90-92% for rocuronium.","Simultaneous quantification of propofol, ketamine and rocuronium in just 10 μL plasma using liquid chromatography coupled with quadrupole mass spectrometry and its pilot application to a pharmacokinetic study in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30924939/),%,89-93,12805,DB00728,Rocuronium
,30924939,recovery,"Mean recovery from plasma was 91-93% for propofol, 89-93% for ketamine and 90-92% for rocuronium.","Simultaneous quantification of propofol, ketamine and rocuronium in just 10 μL plasma using liquid chromatography coupled with quadrupole mass spectrometry and its pilot application to a pharmacokinetic study in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30924939/),%,90-92,12806,DB00728,Rocuronium
,30924939,Mean plasma concentrations,"Mean plasma concentrations with standard deviations were propofol 2.0 μg/mL ±0.5%, ketamine 3.9 μg/mL ±1.0% and rocuronium 3.2 μg/mL ±0.8% during ventilation.","Simultaneous quantification of propofol, ketamine and rocuronium in just 10 μL plasma using liquid chromatography coupled with quadrupole mass spectrometry and its pilot application to a pharmacokinetic study in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30924939/),[μg] / [ml],2.0,12807,DB00728,Rocuronium
,30924939,Mean plasma concentrations,"Mean plasma concentrations with standard deviations were propofol 2.0 μg/mL ±0.5%, ketamine 3.9 μg/mL ±1.0% and rocuronium 3.2 μg/mL ±0.8% during ventilation.","Simultaneous quantification of propofol, ketamine and rocuronium in just 10 μL plasma using liquid chromatography coupled with quadrupole mass spectrometry and its pilot application to a pharmacokinetic study in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30924939/),μg,3.9,12808,DB00728,Rocuronium
,30924939,Mean plasma concentrations,"Mean plasma concentrations with standard deviations were propofol 2.0 μg/mL ±0.5%, ketamine 3.9 μg/mL ±1.0% and rocuronium 3.2 μg/mL ±0.8% during ventilation.","Simultaneous quantification of propofol, ketamine and rocuronium in just 10 μL plasma using liquid chromatography coupled with quadrupole mass spectrometry and its pilot application to a pharmacokinetic study in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30924939/),[μg] / [ml],3.2,12809,DB00728,Rocuronium
,17018564,maximum,"After 30 and 60 min these maximum blocks amounted to 49% (SEM=7.6) and 79% (SEM=4.2), respectively.","Time course of action of sugammadex (Org 25969) on rocuronium-induced block in the Rhesus monkey, using a simple model of equilibration of complex formation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17018564/),%,49,16054,DB00728,Rocuronium
,17018564,half-life,The estimated half-life of sugammadex in Rhesus monkey is 30 (SEM=4.9) min.,"Time course of action of sugammadex (Org 25969) on rocuronium-induced block in the Rhesus monkey, using a simple model of equilibration of complex formation. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17018564/),min,30,16055,DB00728,Rocuronium
,7741284,weight-normalized plasma clearance,"With mixed-effects modeling, weight-normalized plasma clearance varied with weight (P < 0.01), being 79.4 ml.min-1 + 3.13 ml.kg-1.min-1.",Pharmacokinetics of rocuronium in children aged 4-11 years. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7741284/),[ml] / [min],79.4,18862,DB00728,Rocuronium
,7741284,weight-normalized distributional clearance,"Neither weight-normalized distributional clearance (2.67 ml.kg-1.min-1), weight-normalized central compartment volume (106 ml/kg), nor weight-normalized volume of distribution at steady-state (224 ml/kg) varied with weight, height, or age.",Pharmacokinetics of rocuronium in children aged 4-11 years. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7741284/),[ml] / [kg·min],2.67,18863,DB00728,Rocuronium
,7741284,weight-normalized central compartment volume,"Neither weight-normalized distributional clearance (2.67 ml.kg-1.min-1), weight-normalized central compartment volume (106 ml/kg), nor weight-normalized volume of distribution at steady-state (224 ml/kg) varied with weight, height, or age.",Pharmacokinetics of rocuronium in children aged 4-11 years. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7741284/),[ml] / [kg],106,18864,DB00728,Rocuronium
,7741284,weight-normalized volume of distribution at steady-state,"Neither weight-normalized distributional clearance (2.67 ml.kg-1.min-1), weight-normalized central compartment volume (106 ml/kg), nor weight-normalized volume of distribution at steady-state (224 ml/kg) varied with weight, height, or age.",Pharmacokinetics of rocuronium in children aged 4-11 years. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7741284/),[ml] / [kg],224,18865,DB00728,Rocuronium
,26899676,Onset time,"Onset time at the masseter (mean ± SD, 1.5 ± 0.9 min) was faster than at the adductor pollicis (2.7 ± 1.4 min, P < 0.05).",Rocuronium pharmacokinetics and pharmacodynamics in the adductor pollicis and masseter muscles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26899676/),min,1.5,19617,DB00728,Rocuronium
,26899676,Onset time,"Onset time at the masseter (mean ± SD, 1.5 ± 0.9 min) was faster than at the adductor pollicis (2.7 ± 1.4 min, P < 0.05).",Rocuronium pharmacokinetics and pharmacodynamics in the adductor pollicis and masseter muscles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26899676/),min,2.7,19618,DB00728,Rocuronium
,26899676,time to TOF ratio,"Recovery, measured as the time to TOF ratio = 0.9 was similar between muscles 29.9 ± 6.7 (adductor pollicis) vs. 29.3 ± 8.1 (masseter).",Rocuronium pharmacokinetics and pharmacodynamics in the adductor pollicis and masseter muscles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26899676/),,0.9,19619,DB00728,Rocuronium
,26899676,time to TOF ratio,"Recovery, measured as the time to TOF ratio = 0.9 was similar between muscles 29.9 ± 6.7 (adductor pollicis) vs. 29.3 ± 8.1 (masseter).",Rocuronium pharmacokinetics and pharmacodynamics in the adductor pollicis and masseter muscles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26899676/),,29.9,19620,DB00728,Rocuronium
,26899676,time to TOF ratio,"Recovery, measured as the time to TOF ratio = 0.9 was similar between muscles 29.9 ± 6.7 (adductor pollicis) vs. 29.3 ± 8.1 (masseter).",Rocuronium pharmacokinetics and pharmacodynamics in the adductor pollicis and masseter muscles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26899676/),,29.3,19621,DB00728,Rocuronium
,26899676,half-time (teq),"The estimated pharmacodynamic parameters [mean (95% CI)] of the adductor pollicis muscle and the masseter muscle were; plasma effect-site equilibration half-time (teq) 3.25 (2.34, 3.69) min vs. 2.86 (1.83, 3.29) min, (∆OFV 383.665); Ce50 of 1.24 (1.13, 1.56) mg/l vs. 1.19 (1.00, 1.21) mg/l, (∆OFV 184.284); Hill coefficient of 3.97 (3.82, 5.62) vs. 4.68 (3.83, 5.71), (∆OFV 78.906).",Rocuronium pharmacokinetics and pharmacodynamics in the adductor pollicis and masseter muscles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26899676/),min,3.25,19622,DB00728,Rocuronium
,26899676,half-time (teq),"The estimated pharmacodynamic parameters [mean (95% CI)] of the adductor pollicis muscle and the masseter muscle were; plasma effect-site equilibration half-time (teq) 3.25 (2.34, 3.69) min vs. 2.86 (1.83, 3.29) min, (∆OFV 383.665); Ce50 of 1.24 (1.13, 1.56) mg/l vs. 1.19 (1.00, 1.21) mg/l, (∆OFV 184.284); Hill coefficient of 3.97 (3.82, 5.62) vs. 4.68 (3.83, 5.71), (∆OFV 78.906).",Rocuronium pharmacokinetics and pharmacodynamics in the adductor pollicis and masseter muscles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26899676/),min,2.86,19623,DB00728,Rocuronium
,26899676,Ce50,"The estimated pharmacodynamic parameters [mean (95% CI)] of the adductor pollicis muscle and the masseter muscle were; plasma effect-site equilibration half-time (teq) 3.25 (2.34, 3.69) min vs. 2.86 (1.83, 3.29) min, (∆OFV 383.665); Ce50 of 1.24 (1.13, 1.56) mg/l vs. 1.19 (1.00, 1.21) mg/l, (∆OFV 184.284); Hill coefficient of 3.97 (3.82, 5.62) vs. 4.68 (3.83, 5.71), (∆OFV 78.906).",Rocuronium pharmacokinetics and pharmacodynamics in the adductor pollicis and masseter muscles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26899676/),[mg] / [l],1.24,19624,DB00728,Rocuronium
,26899676,Ce50,"The estimated pharmacodynamic parameters [mean (95% CI)] of the adductor pollicis muscle and the masseter muscle were; plasma effect-site equilibration half-time (teq) 3.25 (2.34, 3.69) min vs. 2.86 (1.83, 3.29) min, (∆OFV 383.665); Ce50 of 1.24 (1.13, 1.56) mg/l vs. 1.19 (1.00, 1.21) mg/l, (∆OFV 184.284); Hill coefficient of 3.97 (3.82, 5.62) vs. 4.68 (3.83, 5.71), (∆OFV 78.906).",Rocuronium pharmacokinetics and pharmacodynamics in the adductor pollicis and masseter muscles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26899676/),[mg] / [l],1.19,19625,DB00728,Rocuronium
,26899676,Hill coefficient,"The estimated pharmacodynamic parameters [mean (95% CI)] of the adductor pollicis muscle and the masseter muscle were; plasma effect-site equilibration half-time (teq) 3.25 (2.34, 3.69) min vs. 2.86 (1.83, 3.29) min, (∆OFV 383.665); Ce50 of 1.24 (1.13, 1.56) mg/l vs. 1.19 (1.00, 1.21) mg/l, (∆OFV 184.284); Hill coefficient of 3.97 (3.82, 5.62) vs. 4.68 (3.83, 5.71), (∆OFV 78.906).",Rocuronium pharmacokinetics and pharmacodynamics in the adductor pollicis and masseter muscles. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26899676/),,3.97,19626,DB00728,Rocuronium
,26899676,Hill coefficient,"The estimated pharmacodynamic parameters [mean (95% CI)] of the adductor pollicis muscle and the masseter muscle were; plasma effect-site equilibration half-time (teq) 3.25 (2.34, 3.69) min vs. 2.86 (1.83, 3.29) min, (∆OFV 383.665); Ce50 of 1.24 (1.13, 1.56) mg/l vs. 1.19 (1.00, 1.21) mg/l, (∆OFV 184.284); Hill coefficient of 3.97 (3.82, 5.62) vs. 4.68 (3.83, 5.71), (∆OFV 78.906).",Rocuronium pharmacokinetics and pharmacodynamics in the adductor pollicis and masseter muscles. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26899676/),,4.68,19627,DB00728,Rocuronium
,9135303,requirements,"Median requirements for rocuronium were 27.4 (range 14.5-68.3) mg h-1 and 43.7 (30.9-50.3) mg h-1 in patients in the bolus and infusion groups, respectively.",Pharmacodynamics and pharmacokinetics of rocuronium in intensive care patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9135303/),[mg] / [h],27.4,31080,DB00728,Rocuronium
,9135303,requirements,"Median requirements for rocuronium were 27.4 (range 14.5-68.3) mg h-1 and 43.7 (30.9-50.3) mg h-1 in patients in the bolus and infusion groups, respectively.",Pharmacodynamics and pharmacokinetics of rocuronium in intensive care patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9135303/),[mg] / [h],43.7,31081,DB00728,Rocuronium
,9135303,total duration,"Median total duration of rocuronium administration was 29.0 (12.4-95.5) h and 63.4 (24.0-140.3) h, respectively.",Pharmacodynamics and pharmacokinetics of rocuronium in intensive care patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9135303/),h,29.0,31082,DB00728,Rocuronium
,9135303,total duration,"Median total duration of rocuronium administration was 29.0 (12.4-95.5) h and 63.4 (24.0-140.3) h, respectively.",Pharmacodynamics and pharmacokinetics of rocuronium in intensive care patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9135303/),h,63.4,31083,DB00728,Rocuronium
,9135303,time,"Median time from administration of the last bolus dose and end of infusion to recovery of the fourth twitch in the TOF was 100 (45-300) min and 60 (15-155) min, respectively.",Pharmacodynamics and pharmacokinetics of rocuronium in intensive care patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9135303/),min,100,31084,DB00728,Rocuronium
,9135303,time,"Median time from administration of the last bolus dose and end of infusion to recovery of the fourth twitch in the TOF was 100 (45-300) min and 60 (15-155) min, respectively.",Pharmacodynamics and pharmacokinetics of rocuronium in intensive care patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9135303/),min,60,31085,DB00728,Rocuronium
,9135303,plasma clearance (Cl),"Mean plasma clearance (Cl), steady-state distribution volume (Vss), mean residence time (MRT) and elimination half-life (T1/2 beta) were 3.16 (SD 1.15) ml kg-1 min-1, 769 (334) ml kg-1, 262 (120) min and 337 (163) min, respectively.",Pharmacodynamics and pharmacokinetics of rocuronium in intensive care patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9135303/),[ml] / [kg·min],3.16,31086,DB00728,Rocuronium
,9135303,steady-state distribution volume (Vss),"Mean plasma clearance (Cl), steady-state distribution volume (Vss), mean residence time (MRT) and elimination half-life (T1/2 beta) were 3.16 (SD 1.15) ml kg-1 min-1, 769 (334) ml kg-1, 262 (120) min and 337 (163) min, respectively.",Pharmacodynamics and pharmacokinetics of rocuronium in intensive care patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9135303/),[ml] / [kg],769,31087,DB00728,Rocuronium
,9135303,steady-state distribution volume (Vss),"Mean plasma clearance (Cl), steady-state distribution volume (Vss), mean residence time (MRT) and elimination half-life (T1/2 beta) were 3.16 (SD 1.15) ml kg-1 min-1, 769 (334) ml kg-1, 262 (120) min and 337 (163) min, respectively.",Pharmacodynamics and pharmacokinetics of rocuronium in intensive care patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9135303/),min,262,31088,DB00728,Rocuronium
,9135303,mean residence time (MRT),"Mean plasma clearance (Cl), steady-state distribution volume (Vss), mean residence time (MRT) and elimination half-life (T1/2 beta) were 3.16 (SD 1.15) ml kg-1 min-1, 769 (334) ml kg-1, 262 (120) min and 337 (163) min, respectively.",Pharmacodynamics and pharmacokinetics of rocuronium in intensive care patients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9135303/),[ml] / [kg],769,31089,DB00728,Rocuronium
,9135303,mean residence time (MRT),"Mean plasma clearance (Cl), steady-state distribution volume (Vss), mean residence time (MRT) and elimination half-life (T1/2 beta) were 3.16 (SD 1.15) ml kg-1 min-1, 769 (334) ml kg-1, 262 (120) min and 337 (163) min, respectively.",Pharmacodynamics and pharmacokinetics of rocuronium in intensive care patients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9135303/),min,262,31090,DB00728,Rocuronium
,9135303,elimination half-life (T1/2 beta),"Mean plasma clearance (Cl), steady-state distribution volume (Vss), mean residence time (MRT) and elimination half-life (T1/2 beta) were 3.16 (SD 1.15) ml kg-1 min-1, 769 (334) ml kg-1, 262 (120) min and 337 (163) min, respectively.",Pharmacodynamics and pharmacokinetics of rocuronium in intensive care patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9135303/),min,337,31091,DB00728,Rocuronium
,12538375,AUC(OE),The mean AUC(OE) was 25.1 (SD 11.9)% block x h. AUC(PE)-AUC(OE) was significantly larger in the Szenohradszky model when compared with all other pharmacokinetic models.,Target controlled infusion of rocuronium: analysis of effect data to select a pharmacokinetic model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12538375/),%·block·h,25.1,31608,DB00728,Rocuronium
,12374713,steady-state serum concentration,"Half of the patients received propofol in an escalating fashion, initially targeting an estimated steady-state serum concentration of 3 microg x mL-1, which was then doubled.",Propofol decreases cerebral blood flow velocity in anesthetized children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374713/),[μg] / [ml],3,36746,DB00728,Rocuronium
,9197300,Cl,"During the paleohepatic and anhepatic periods, the typical value of Cl was 2.47 ml x kg(-1) x min(-1) and was not influenced by the magnitude of preexisting liver disease (as evidenced by prothrombin time, bilirubin, serum albumin, alanine transaminase [ALT], and aspartate transaminase [AST]).",Pharmacokinetics of rocuronium during the three stages of liver transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9197300/),[ml] / [kg·min],2.47,39904,DB00728,Rocuronium
,9197300,Cl,"During the neohepatic period, the typical value of Cl varied as a function of the duration of warm ischemia of the hepatic allograft and was 2.72 ml x kg(-1) x min(-1) for a patient with an average 60-min period of warm ischemia; time to neuromuscular recovery varied as a function of Cl.",Pharmacokinetics of rocuronium during the three stages of liver transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9197300/),[ml] / [kg·min],2.72,39905,DB00728,Rocuronium
,20876699,T₄/T₁ ratio,The primary efficacy variable was time from the start of sugammadex administration to recovery of T₄/T₁ ratio to 0.9.,Sugammadex rapidly reverses moderate rocuronium- or vecuronium-induced neuromuscular block during sevoflurane anaesthesia: a dose-response relationship. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20876699/),,0.9,40194,DB00728,Rocuronium
,20876699,recovery times of T₄/T₁ ratio,"A statistically significant dose-response relationship was demonstrated for mean recovery times of T₄/T₁ ratio to 0.9 with increasing sugammadex dose with both NMBAs: rocuronium, 96.3 min (placebo) to 1.5 min (sugammadex 4.0 mg kg⁻¹); vecuronium, 79.0 min (placebo) to 3.0 min (sugammadex 4.0 mg kg⁻¹).",Sugammadex rapidly reverses moderate rocuronium- or vecuronium-induced neuromuscular block during sevoflurane anaesthesia: a dose-response relationship. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20876699/),min,0.9,40195,DB00728,Rocuronium
,20876699,recovery times of T₄/T₁ ratio,"A statistically significant dose-response relationship was demonstrated for mean recovery times of T₄/T₁ ratio to 0.9 with increasing sugammadex dose with both NMBAs: rocuronium, 96.3 min (placebo) to 1.5 min (sugammadex 4.0 mg kg⁻¹); vecuronium, 79.0 min (placebo) to 3.0 min (sugammadex 4.0 mg kg⁻¹).",Sugammadex rapidly reverses moderate rocuronium- or vecuronium-induced neuromuscular block during sevoflurane anaesthesia: a dose-response relationship. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20876699/),min,96.3,40196,DB00728,Rocuronium
,20876699,recovery times of T₄/T₁ ratio,"A statistically significant dose-response relationship was demonstrated for mean recovery times of T₄/T₁ ratio to 0.9 with increasing sugammadex dose with both NMBAs: rocuronium, 96.3 min (placebo) to 1.5 min (sugammadex 4.0 mg kg⁻¹); vecuronium, 79.0 min (placebo) to 3.0 min (sugammadex 4.0 mg kg⁻¹).",Sugammadex rapidly reverses moderate rocuronium- or vecuronium-induced neuromuscular block during sevoflurane anaesthesia: a dose-response relationship. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20876699/),min,1.5,40197,DB00728,Rocuronium
,20876699,recovery times of T₄/T₁ ratio,"A statistically significant dose-response relationship was demonstrated for mean recovery times of T₄/T₁ ratio to 0.9 with increasing sugammadex dose with both NMBAs: rocuronium, 96.3 min (placebo) to 1.5 min (sugammadex 4.0 mg kg⁻¹); vecuronium, 79.0 min (placebo) to 3.0 min (sugammadex 4.0 mg kg⁻¹).",Sugammadex rapidly reverses moderate rocuronium- or vecuronium-induced neuromuscular block during sevoflurane anaesthesia: a dose-response relationship. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20876699/),min,79.0,40198,DB00728,Rocuronium
,20876699,recovery times of T₄/T₁ ratio,"A statistically significant dose-response relationship was demonstrated for mean recovery times of T₄/T₁ ratio to 0.9 with increasing sugammadex dose with both NMBAs: rocuronium, 96.3 min (placebo) to 1.5 min (sugammadex 4.0 mg kg⁻¹); vecuronium, 79.0 min (placebo) to 3.0 min (sugammadex 4.0 mg kg⁻¹).",Sugammadex rapidly reverses moderate rocuronium- or vecuronium-induced neuromuscular block during sevoflurane anaesthesia: a dose-response relationship. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20876699/),min,3.0,40199,DB00728,Rocuronium
,11263576,extraction recovery,The extraction recovery averaged 59% for rocuronium and 83% for the internal standard.,Quantitative determination of rocuronium in human plasma by liquid chromatography-electrospray ionization mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11263576/),%,59,53798,DB00728,Rocuronium
,11263576,extraction recovery,The extraction recovery averaged 59% for rocuronium and 83% for the internal standard.,Quantitative determination of rocuronium in human plasma by liquid chromatography-electrospray ionization mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11263576/),%,83,53799,DB00728,Rocuronium
,11263576,limit of quantification (LOQ),"The limit of quantification (LOQ), using 500 microl of plasma, was 25 ng/ml.",Quantitative determination of rocuronium in human plasma by liquid chromatography-electrospray ionization mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11263576/),[ng] / [ml],25,53800,DB00728,Rocuronium
,11135721,CO,The CO of the patients varied from 2.43 to 5.59 l/min.,Recirculatory pharmacokinetics and pharmacodynamics of rocuronium in patients: the influence of cardiac output. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11135721/),[l] / [min],2.43 to 5.59,56722,DB00728,Rocuronium
,11135721,Total distribution volume,Total distribution volume of rocuronium was 17.3 +/- 4.8 l (mean +/- SD).,Recirculatory pharmacokinetics and pharmacodynamics of rocuronium in patients: the influence of cardiac output. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11135721/),l,17.3,56723,DB00728,Rocuronium
,10500937,Onset time,"Onset time was shorter (NS) in the obese compared with normal weight (obese weight: 65 +/- 16, normal weight: 100 +/- 39 s, mean +/- SD).",Pharmacokinetics of rocuronium bromide in obese female patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10500937/),s,65,64926,DB00728,Rocuronium
,10500937,Onset time,"Onset time was shorter (NS) in the obese compared with normal weight (obese weight: 65 +/- 16, normal weight: 100 +/- 39 s, mean +/- SD).",Pharmacokinetics of rocuronium bromide in obese female patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10500937/),s,100,64927,DB00728,Rocuronium
,10500937,Du,"Duration 25% (obese weight: 29.5 +/- 5.3, normal weight: 28.4 +/- 5.3 min) and spontaneous recovery time (obese weight: 12.6 +/- 2.7, normal weight: 12.5 +/- 2.3 min) did not show any differences between the two groups.",Pharmacokinetics of rocuronium bromide in obese female patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10500937/),min,29.5,64928,DB00728,Rocuronium
,10500937,Du,"Duration 25% (obese weight: 29.5 +/- 5.3, normal weight: 28.4 +/- 5.3 min) and spontaneous recovery time (obese weight: 12.6 +/- 2.7, normal weight: 12.5 +/- 2.3 min) did not show any differences between the two groups.",Pharmacokinetics of rocuronium bromide in obese female patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10500937/),min,28,64929,DB00728,Rocuronium
,10500937,spontaneous recovery time,"Duration 25% (obese weight: 29.5 +/- 5.3, normal weight: 28.4 +/- 5.3 min) and spontaneous recovery time (obese weight: 12.6 +/- 2.7, normal weight: 12.5 +/- 2.3 min) did not show any differences between the two groups.",Pharmacokinetics of rocuronium bromide in obese female patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10500937/),min,12.6,64930,DB00728,Rocuronium
,10500937,spontaneous recovery time,"Duration 25% (obese weight: 29.5 +/- 5.3, normal weight: 28.4 +/- 5.3 min) and spontaneous recovery time (obese weight: 12.6 +/- 2.7, normal weight: 12.5 +/- 2.3 min) did not show any differences between the two groups.",Pharmacokinetics of rocuronium bromide in obese female patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10500937/),min,12.5,64931,DB00728,Rocuronium
,10500937,volume of distribution at steady state Vss,The volume of distribution at steady state Vss (mL kg-1) was 208 +/- 56 in normal weight and 169 +/- 37 in obese weight.,Pharmacokinetics of rocuronium bromide in obese female patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10500937/),[ml] / [kg],208,64932,DB00728,Rocuronium
,10500937,volume of distribution at steady state Vss,The volume of distribution at steady state Vss (mL kg-1) was 208 +/- 56 in normal weight and 169 +/- 37 in obese weight.,Pharmacokinetics of rocuronium bromide in obese female patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10500937/),[ml] / [kg],169,64933,DB00728,Rocuronium
,10500937,Distribution (T1/2 alpha),"Distribution (T1/2 alpha) and elimination half-life (T1/2 beta) as well as mean residence time were 15.6 +/- 3.7, 70.3 +/- 23.9 and 53.2 +/- 9.8 min in normal weight and 16.9 +/- 3.8, 75.5 +/- 25.5 and 51.1 +/- 18.9 min in obese weight, respectively.",Pharmacokinetics of rocuronium bromide in obese female patients. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10500937/),min,15.6,64934,DB00728,Rocuronium
,10500937,Distribution (T1/2 alpha),"Distribution (T1/2 alpha) and elimination half-life (T1/2 beta) as well as mean residence time were 15.6 +/- 3.7, 70.3 +/- 23.9 and 53.2 +/- 9.8 min in normal weight and 16.9 +/- 3.8, 75.5 +/- 25.5 and 51.1 +/- 18.9 min in obese weight, respectively.",Pharmacokinetics of rocuronium bromide in obese female patients. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10500937/),min,16.9,64935,DB00728,Rocuronium
,10500937,elimination half-life (T1/2 beta),"Distribution (T1/2 alpha) and elimination half-life (T1/2 beta) as well as mean residence time were 15.6 +/- 3.7, 70.3 +/- 23.9 and 53.2 +/- 9.8 min in normal weight and 16.9 +/- 3.8, 75.5 +/- 25.5 and 51.1 +/- 18.9 min in obese weight, respectively.",Pharmacokinetics of rocuronium bromide in obese female patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10500937/),min,70.3,64936,DB00728,Rocuronium
,10500937,elimination half-life (T1/2 beta),"Distribution (T1/2 alpha) and elimination half-life (T1/2 beta) as well as mean residence time were 15.6 +/- 3.7, 70.3 +/- 23.9 and 53.2 +/- 9.8 min in normal weight and 16.9 +/- 3.8, 75.5 +/- 25.5 and 51.1 +/- 18.9 min in obese weight, respectively.",Pharmacokinetics of rocuronium bromide in obese female patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10500937/),min,53.2,64937,DB00728,Rocuronium
,10500937,elimination half-life (T1/2 beta),"Distribution (T1/2 alpha) and elimination half-life (T1/2 beta) as well as mean residence time were 15.6 +/- 3.7, 70.3 +/- 23.9 and 53.2 +/- 9.8 min in normal weight and 16.9 +/- 3.8, 75.5 +/- 25.5 and 51.1 +/- 18.9 min in obese weight, respectively.",Pharmacokinetics of rocuronium bromide in obese female patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10500937/),min,16.9,64938,DB00728,Rocuronium
,10500937,elimination half-life (T1/2 beta),"Distribution (T1/2 alpha) and elimination half-life (T1/2 beta) as well as mean residence time were 15.6 +/- 3.7, 70.3 +/- 23.9 and 53.2 +/- 9.8 min in normal weight and 16.9 +/- 3.8, 75.5 +/- 25.5 and 51.1 +/- 18.9 min in obese weight, respectively.",Pharmacokinetics of rocuronium bromide in obese female patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10500937/),min,75.5,64939,DB00728,Rocuronium
,10500937,mean residence time,"Distribution (T1/2 alpha) and elimination half-life (T1/2 beta) as well as mean residence time were 15.6 +/- 3.7, 70.3 +/- 23.9 and 53.2 +/- 9.8 min in normal weight and 16.9 +/- 3.8, 75.5 +/- 25.5 and 51.1 +/- 18.9 min in obese weight, respectively.",Pharmacokinetics of rocuronium bromide in obese female patients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10500937/),min,53.2,64940,DB00728,Rocuronium
,10500937,mean residence time,"Distribution (T1/2 alpha) and elimination half-life (T1/2 beta) as well as mean residence time were 15.6 +/- 3.7, 70.3 +/- 23.9 and 53.2 +/- 9.8 min in normal weight and 16.9 +/- 3.8, 75.5 +/- 25.5 and 51.1 +/- 18.9 min in obese weight, respectively.",Pharmacokinetics of rocuronium bromide in obese female patients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10500937/),min,75.5,64941,DB00728,Rocuronium
,10500937,mean residence time,"Distribution (T1/2 alpha) and elimination half-life (T1/2 beta) as well as mean residence time were 15.6 +/- 3.7, 70.3 +/- 23.9 and 53.2 +/- 9.8 min in normal weight and 16.9 +/- 3.8, 75.5 +/- 25.5 and 51.1 +/- 18.9 min in obese weight, respectively.",Pharmacokinetics of rocuronium bromide in obese female patients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10500937/),min,51.1,64942,DB00728,Rocuronium
,10500937,plasma clearance,"Also, no differences were observed in plasma clearance (3.89 +/- 0.58 in normal weight and 3.62 +/- 1.42 mL kg-1 min-1 obese weight).",Pharmacokinetics of rocuronium bromide in obese female patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10500937/),[ml] / [kg·min],3.89,64943,DB00728,Rocuronium
,10500937,plasma clearance,"Also, no differences were observed in plasma clearance (3.89 +/- 0.58 in normal weight and 3.62 +/- 1.42 mL kg-1 min-1 obese weight).",Pharmacokinetics of rocuronium bromide in obese female patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10500937/),[ml] / [kg·min],3.62,64944,DB00728,Rocuronium
,9215021,administered dose,"The mean administered dose was 0.32 (SD 0.08) mg kg-1 and 0.4 (0.1) mg kg-1 for infants and children, respectively.",Pharmacokinetics and pharmacokinetic-dynamic modelling of rocuronium in infants and children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9215021/),[mg] / [kg],0.32,69457,DB00728,Rocuronium
,9215021,administered dose,"The mean administered dose was 0.32 (SD 0.08) mg kg-1 and 0.4 (0.1) mg kg-1 for infants and children, respectively.",Pharmacokinetics and pharmacokinetic-dynamic modelling of rocuronium in infants and children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9215021/),[mg] / [kg],0.4,69458,DB00728,Rocuronium
,9215021,plasma clearance,"Infants differed from children in plasma clearance (4.2 (0.4) vs 6.7 (1.1) ml min-1 kg-1), distribution volume at steady state (231 (32) vs 165 (44) ml kg-1), mean residence time (56 (10) vs 26 (9) min), concentration in the effect compartment at 50% block (1.2 (0.4) vs 1.7 (0.4) mg litre-1) and the slope of the concentration-effect relationship (5.7 (1.3) vs 3.9 (0.5)).",Pharmacokinetics and pharmacokinetic-dynamic modelling of rocuronium in infants and children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9215021/),[ml] / [kg·min],4.2,69459,DB00728,Rocuronium
,9215021,plasma clearance,"Infants differed from children in plasma clearance (4.2 (0.4) vs 6.7 (1.1) ml min-1 kg-1), distribution volume at steady state (231 (32) vs 165 (44) ml kg-1), mean residence time (56 (10) vs 26 (9) min), concentration in the effect compartment at 50% block (1.2 (0.4) vs 1.7 (0.4) mg litre-1) and the slope of the concentration-effect relationship (5.7 (1.3) vs 3.9 (0.5)).",Pharmacokinetics and pharmacokinetic-dynamic modelling of rocuronium in infants and children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9215021/),[ml] / [kg·min],6.7,69460,DB00728,Rocuronium
,9215021,distribution volume at steady state,"Infants differed from children in plasma clearance (4.2 (0.4) vs 6.7 (1.1) ml min-1 kg-1), distribution volume at steady state (231 (32) vs 165 (44) ml kg-1), mean residence time (56 (10) vs 26 (9) min), concentration in the effect compartment at 50% block (1.2 (0.4) vs 1.7 (0.4) mg litre-1) and the slope of the concentration-effect relationship (5.7 (1.3) vs 3.9 (0.5)).",Pharmacokinetics and pharmacokinetic-dynamic modelling of rocuronium in infants and children. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9215021/),[ml] / [kg],231,69461,DB00728,Rocuronium
,9215021,distribution volume at steady state,"Infants differed from children in plasma clearance (4.2 (0.4) vs 6.7 (1.1) ml min-1 kg-1), distribution volume at steady state (231 (32) vs 165 (44) ml kg-1), mean residence time (56 (10) vs 26 (9) min), concentration in the effect compartment at 50% block (1.2 (0.4) vs 1.7 (0.4) mg litre-1) and the slope of the concentration-effect relationship (5.7 (1.3) vs 3.9 (0.5)).",Pharmacokinetics and pharmacokinetic-dynamic modelling of rocuronium in infants and children. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9215021/),[ml] / [kg],165,69462,DB00728,Rocuronium
,9215021,mean residence time,"Infants differed from children in plasma clearance (4.2 (0.4) vs 6.7 (1.1) ml min-1 kg-1), distribution volume at steady state (231 (32) vs 165 (44) ml kg-1), mean residence time (56 (10) vs 26 (9) min), concentration in the effect compartment at 50% block (1.2 (0.4) vs 1.7 (0.4) mg litre-1) and the slope of the concentration-effect relationship (5.7 (1.3) vs 3.9 (0.5)).",Pharmacokinetics and pharmacokinetic-dynamic modelling of rocuronium in infants and children. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9215021/),min,56,69463,DB00728,Rocuronium
,9215021,mean residence time,"Infants differed from children in plasma clearance (4.2 (0.4) vs 6.7 (1.1) ml min-1 kg-1), distribution volume at steady state (231 (32) vs 165 (44) ml kg-1), mean residence time (56 (10) vs 26 (9) min), concentration in the effect compartment at 50% block (1.2 (0.4) vs 1.7 (0.4) mg litre-1) and the slope of the concentration-effect relationship (5.7 (1.3) vs 3.9 (0.5)).",Pharmacokinetics and pharmacokinetic-dynamic modelling of rocuronium in infants and children. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9215021/),min,26,69464,DB00728,Rocuronium
,9215021,concentration in the effect compartment at 50% block,"Infants differed from children in plasma clearance (4.2 (0.4) vs 6.7 (1.1) ml min-1 kg-1), distribution volume at steady state (231 (32) vs 165 (44) ml kg-1), mean residence time (56 (10) vs 26 (9) min), concentration in the effect compartment at 50% block (1.2 (0.4) vs 1.7 (0.4) mg litre-1) and the slope of the concentration-effect relationship (5.7 (1.3) vs 3.9 (0.5)).",Pharmacokinetics and pharmacokinetic-dynamic modelling of rocuronium in infants and children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9215021/),[mg] / [l],1.2,69465,DB00728,Rocuronium
,9215021,concentration in the effect compartment at 50% block,"Infants differed from children in plasma clearance (4.2 (0.4) vs 6.7 (1.1) ml min-1 kg-1), distribution volume at steady state (231 (32) vs 165 (44) ml kg-1), mean residence time (56 (10) vs 26 (9) min), concentration in the effect compartment at 50% block (1.2 (0.4) vs 1.7 (0.4) mg litre-1) and the slope of the concentration-effect relationship (5.7 (1.3) vs 3.9 (0.5)).",Pharmacokinetics and pharmacokinetic-dynamic modelling of rocuronium in infants and children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9215021/),[mg] / [l],1.7,69466,DB00728,Rocuronium
,9215021,ED90,"Calculated mean ED90 values were 0.26 and 0.34 mg kg-1 for infants and children, respectively.",Pharmacokinetics and pharmacokinetic-dynamic modelling of rocuronium in infants and children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9215021/),[mg] / [kg],0.26,69467,DB00728,Rocuronium
,9215021,ED90,"Calculated mean ED90 values were 0.26 and 0.34 mg kg-1 for infants and children, respectively.",Pharmacokinetics and pharmacokinetic-dynamic modelling of rocuronium in infants and children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9215021/),[mg] / [kg],0.34,69468,DB00728,Rocuronium
,15816565,time to recovery,Clinical duration and the time to recovery of the train-of-four to 70% were prolonged in the renal failure group compared to control; 49 vs.,Pharmacokinetics and pharmacodynamics of rocuronium in patients with and without renal failure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15816565/),,49,70584,DB00728,Rocuronium
,16634542,Onset times,"Onset times for patients receiving 0.3 mg x kg(-1), 0.6 mg x kg(-1) or 0.9 mg x kg(-1) were 271.5 s, 140.0s and 125.4s, respectively.","[Neuromuscular blocking effects, pharmacokinetics and safety of Org 9426 (rocuronium bromide) in Japanese patients]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16634542/),s,271.5,70647,DB00728,Rocuronium
,16634542,Onset times,"Onset times for patients receiving 0.3 mg x kg(-1), 0.6 mg x kg(-1) or 0.9 mg x kg(-1) were 271.5 s, 140.0s and 125.4s, respectively.","[Neuromuscular blocking effects, pharmacokinetics and safety of Org 9426 (rocuronium bromide) in Japanese patients]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16634542/),s,140.0,70648,DB00728,Rocuronium
,16634542,Onset times,"Onset times for patients receiving 0.3 mg x kg(-1), 0.6 mg x kg(-1) or 0.9 mg x kg(-1) were 271.5 s, 140.0s and 125.4s, respectively.","[Neuromuscular blocking effects, pharmacokinetics and safety of Org 9426 (rocuronium bromide) in Japanese patients]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16634542/),s,125.4,70649,DB00728,Rocuronium
,16634542,25% recovery of twitch height,"There was a dose-dependent increase in clinical durations until 25% recovery of twitch height (17.4 min in 0.3 mg x kg(-1) group, 37.2 min in 0.6 mg x kg(-1) and 60.4 min in 0.9 mg x kg(-1) group).","[Neuromuscular blocking effects, pharmacokinetics and safety of Org 9426 (rocuronium bromide) in Japanese patients]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16634542/),min,17.4,70650,DB00728,Rocuronium
,16634542,25% recovery of twitch height,"There was a dose-dependent increase in clinical durations until 25% recovery of twitch height (17.4 min in 0.3 mg x kg(-1) group, 37.2 min in 0.6 mg x kg(-1) and 60.4 min in 0.9 mg x kg(-1) group).","[Neuromuscular blocking effects, pharmacokinetics and safety of Org 9426 (rocuronium bromide) in Japanese patients]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16634542/),min,37.2,70651,DB00728,Rocuronium
,16634542,25% recovery of twitch height,"There was a dose-dependent increase in clinical durations until 25% recovery of twitch height (17.4 min in 0.3 mg x kg(-1) group, 37.2 min in 0.6 mg x kg(-1) and 60.4 min in 0.9 mg x kg(-1) group).","[Neuromuscular blocking effects, pharmacokinetics and safety of Org 9426 (rocuronium bromide) in Japanese patients]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16634542/),min,60.4,70652,DB00728,Rocuronium
,16634542,elimination half life,"Pharmacokinetic study revealed that elimination half life, steady state volume of distribution and plasma clearance of Org 9426 were 48-76 min, 146-181 ml x kg(-1), and 3.8-4.5 ml x min(-1) x kg(-1), respectively.","[Neuromuscular blocking effects, pharmacokinetics and safety of Org 9426 (rocuronium bromide) in Japanese patients]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16634542/),min,48-76,70653,DB00728,Rocuronium
,16634542,steady state volume of distribution,"Pharmacokinetic study revealed that elimination half life, steady state volume of distribution and plasma clearance of Org 9426 were 48-76 min, 146-181 ml x kg(-1), and 3.8-4.5 ml x min(-1) x kg(-1), respectively.","[Neuromuscular blocking effects, pharmacokinetics and safety of Org 9426 (rocuronium bromide) in Japanese patients]. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16634542/),[ml] / [kg],146-181,70654,DB00728,Rocuronium
,16634542,plasma clearance,"Pharmacokinetic study revealed that elimination half life, steady state volume of distribution and plasma clearance of Org 9426 were 48-76 min, 146-181 ml x kg(-1), and 3.8-4.5 ml x min(-1) x kg(-1), respectively.","[Neuromuscular blocking effects, pharmacokinetics and safety of Org 9426 (rocuronium bromide) in Japanese patients]. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16634542/),[ml] / [kg·min],3.8-4.5,70655,DB00728,Rocuronium
,16873389,effective dose(95) (,Rocuronium effective dose(95) (ED(95)) was 26% lower (P<0.05) in the ANH group [283.4 (92.0) microg kg(-1)] compared with the control group [383.5 (127.3) microg kg(-1)].,"Influence of acute normovolaemic haemodilution on the dose-response relationship, time-course of action and pharmacokinetics of rocuronium bromide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16873389/),[μg] / [kg],283.4,73830,DB00728,Rocuronium
,16873389,effective dose(95) (,Rocuronium effective dose(95) (ED(95)) was 26% lower (P<0.05) in the ANH group [283.4 (92.0) microg kg(-1)] compared with the control group [383.5 (127.3) microg kg(-1)].,"Influence of acute normovolaemic haemodilution on the dose-response relationship, time-course of action and pharmacokinetics of rocuronium bromide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16873389/),[μg] / [kg],383.5,73831,DB00728,Rocuronium
,16873389,ED(95)),Rocuronium effective dose(95) (ED(95)) was 26% lower (P<0.05) in the ANH group [283.4 (92.0) microg kg(-1)] compared with the control group [383.5 (127.3) microg kg(-1)].,"Influence of acute normovolaemic haemodilution on the dose-response relationship, time-course of action and pharmacokinetics of rocuronium bromide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16873389/),[μg] / [kg],283.4,73832,DB00728,Rocuronium
,16873389,ED(95)),Rocuronium effective dose(95) (ED(95)) was 26% lower (P<0.05) in the ANH group [283.4 (92.0) microg kg(-1)] compared with the control group [383.5 (127.3) microg kg(-1)].,"Influence of acute normovolaemic haemodilution on the dose-response relationship, time-course of action and pharmacokinetics of rocuronium bromide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16873389/),[μg] / [kg],383.5,73833,DB00728,Rocuronium
,16873389,Times from administration of last incremental dose until 25% of first response of train-of-four (TOF) recovery,"Times from administration of last incremental dose until 25% of first response of train-of-four (TOF) recovery (Dur(25)) and 0.8 TOF ratio recovery (Dur(0.8)) were 28% longer in the ANH group [39.9 (8.4), 66.7 (14.2) min] compared with the control group [31.1 (6.6), 52.1 (15.8) min] (P<0.01, P<0.05), respectively.","Influence of acute normovolaemic haemodilution on the dose-response relationship, time-course of action and pharmacokinetics of rocuronium bromide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16873389/),min,39.9,73834,DB00728,Rocuronium
,16873389,Times from administration of last incremental dose until 25% of first response of train-of-four (TOF) recovery,"Times from administration of last incremental dose until 25% of first response of train-of-four (TOF) recovery (Dur(25)) and 0.8 TOF ratio recovery (Dur(0.8)) were 28% longer in the ANH group [39.9 (8.4), 66.7 (14.2) min] compared with the control group [31.1 (6.6), 52.1 (15.8) min] (P<0.01, P<0.05), respectively.","Influence of acute normovolaemic haemodilution on the dose-response relationship, time-course of action and pharmacokinetics of rocuronium bromide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16873389/),min,66.7,73835,DB00728,Rocuronium
,16873389,Times from administration of last incremental dose until 25% of first response of train-of-four (TOF) recovery,"Times from administration of last incremental dose until 25% of first response of train-of-four (TOF) recovery (Dur(25)) and 0.8 TOF ratio recovery (Dur(0.8)) were 28% longer in the ANH group [39.9 (8.4), 66.7 (14.2) min] compared with the control group [31.1 (6.6), 52.1 (15.8) min] (P<0.01, P<0.05), respectively.","Influence of acute normovolaemic haemodilution on the dose-response relationship, time-course of action and pharmacokinetics of rocuronium bromide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16873389/),min,31.1,73836,DB00728,Rocuronium
,16873389,Times from administration of last incremental dose until 25% of first response of train-of-four (TOF) recovery,"Times from administration of last incremental dose until 25% of first response of train-of-four (TOF) recovery (Dur(25)) and 0.8 TOF ratio recovery (Dur(0.8)) were 28% longer in the ANH group [39.9 (8.4), 66.7 (14.2) min] compared with the control group [31.1 (6.6), 52.1 (15.8) min] (P<0.01, P<0.05), respectively.","Influence of acute normovolaemic haemodilution on the dose-response relationship, time-course of action and pharmacokinetics of rocuronium bromide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16873389/),min,52.1,73837,DB00728,Rocuronium
,16873389,0,"Times from administration of last incremental dose until 25% of first response of train-of-four (TOF) recovery (Dur(25)) and 0.8 TOF ratio recovery (Dur(0.8)) were 28% longer in the ANH group [39.9 (8.4), 66.7 (14.2) min] compared with the control group [31.1 (6.6), 52.1 (15.8) min] (P<0.01, P<0.05), respectively.","Influence of acute normovolaemic haemodilution on the dose-response relationship, time-course of action and pharmacokinetics of rocuronium bromide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16873389/),min,39.9,73838,DB00728,Rocuronium
,16873389,0,"Times from administration of last incremental dose until 25% of first response of train-of-four (TOF) recovery (Dur(25)) and 0.8 TOF ratio recovery (Dur(0.8)) were 28% longer in the ANH group [39.9 (8.4), 66.7 (14.2) min] compared with the control group [31.1 (6.6), 52.1 (15.8) min] (P<0.01, P<0.05), respectively.","Influence of acute normovolaemic haemodilution on the dose-response relationship, time-course of action and pharmacokinetics of rocuronium bromide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16873389/),min,66.7,73839,DB00728,Rocuronium
,16873389,0,"Times from administration of last incremental dose until 25% of first response of train-of-four (TOF) recovery (Dur(25)) and 0.8 TOF ratio recovery (Dur(0.8)) were 28% longer in the ANH group [39.9 (8.4), 66.7 (14.2) min] compared with the control group [31.1 (6.6), 52.1 (15.8) min] (P<0.01, P<0.05), respectively.","Influence of acute normovolaemic haemodilution on the dose-response relationship, time-course of action and pharmacokinetics of rocuronium bromide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16873389/),min,31.1,73840,DB00728,Rocuronium
,16873389,Volume of distribution,"Volume of distribution was higher (P<0.01), central clearance was lower (P<0.05) and terminal elimination half-life was longer (P<0.0001) in the ANH group [234.97 (47.11) ml kg(-1), 4.70 (0.94) ml kg(-1) min(-1), 77.29 (12.25) min] compared with the control group [181.22 (35.73) ml kg(-1), 5.71 (1.29) ml kg(-1) min(-1), 56.86 (10.05) min, respectively].","Influence of acute normovolaemic haemodilution on the dose-response relationship, time-course of action and pharmacokinetics of rocuronium bromide. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16873389/),[ml] / [kg],234.97,73841,DB00728,Rocuronium
,16873389,terminal elimination half-life,"Volume of distribution was higher (P<0.01), central clearance was lower (P<0.05) and terminal elimination half-life was longer (P<0.0001) in the ANH group [234.97 (47.11) ml kg(-1), 4.70 (0.94) ml kg(-1) min(-1), 77.29 (12.25) min] compared with the control group [181.22 (35.73) ml kg(-1), 5.71 (1.29) ml kg(-1) min(-1), 56.86 (10.05) min, respectively].","Influence of acute normovolaemic haemodilution on the dose-response relationship, time-course of action and pharmacokinetics of rocuronium bromide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16873389/),[ml] / [kg],234.97,73842,DB00728,Rocuronium
,16873389,terminal elimination half-life,"Volume of distribution was higher (P<0.01), central clearance was lower (P<0.05) and terminal elimination half-life was longer (P<0.0001) in the ANH group [234.97 (47.11) ml kg(-1), 4.70 (0.94) ml kg(-1) min(-1), 77.29 (12.25) min] compared with the control group [181.22 (35.73) ml kg(-1), 5.71 (1.29) ml kg(-1) min(-1), 56.86 (10.05) min, respectively].","Influence of acute normovolaemic haemodilution on the dose-response relationship, time-course of action and pharmacokinetics of rocuronium bromide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16873389/),[ml] / [kg·min],4.70,73843,DB00728,Rocuronium
,16873389,terminal elimination half-life,"Volume of distribution was higher (P<0.01), central clearance was lower (P<0.05) and terminal elimination half-life was longer (P<0.0001) in the ANH group [234.97 (47.11) ml kg(-1), 4.70 (0.94) ml kg(-1) min(-1), 77.29 (12.25) min] compared with the control group [181.22 (35.73) ml kg(-1), 5.71 (1.29) ml kg(-1) min(-1), 56.86 (10.05) min, respectively].","Influence of acute normovolaemic haemodilution on the dose-response relationship, time-course of action and pharmacokinetics of rocuronium bromide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16873389/),min,77.29,73844,DB00728,Rocuronium
,16873389,terminal elimination half-life,"Volume of distribution was higher (P<0.01), central clearance was lower (P<0.05) and terminal elimination half-life was longer (P<0.0001) in the ANH group [234.97 (47.11) ml kg(-1), 4.70 (0.94) ml kg(-1) min(-1), 77.29 (12.25) min] compared with the control group [181.22 (35.73) ml kg(-1), 5.71 (1.29) ml kg(-1) min(-1), 56.86 (10.05) min, respectively].","Influence of acute normovolaemic haemodilution on the dose-response relationship, time-course of action and pharmacokinetics of rocuronium bromide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16873389/),[ml] / [kg],181.22,73845,DB00728,Rocuronium
,16873389,terminal elimination half-life,"Volume of distribution was higher (P<0.01), central clearance was lower (P<0.05) and terminal elimination half-life was longer (P<0.0001) in the ANH group [234.97 (47.11) ml kg(-1), 4.70 (0.94) ml kg(-1) min(-1), 77.29 (12.25) min] compared with the control group [181.22 (35.73) ml kg(-1), 5.71 (1.29) ml kg(-1) min(-1), 56.86 (10.05) min, respectively].","Influence of acute normovolaemic haemodilution on the dose-response relationship, time-course of action and pharmacokinetics of rocuronium bromide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16873389/),[ml] / [kg·min],5.71,73846,DB00728,Rocuronium
,16873389,terminal elimination half-life,"Volume of distribution was higher (P<0.01), central clearance was lower (P<0.05) and terminal elimination half-life was longer (P<0.0001) in the ANH group [234.97 (47.11) ml kg(-1), 4.70 (0.94) ml kg(-1) min(-1), 77.29 (12.25) min] compared with the control group [181.22 (35.73) ml kg(-1), 5.71 (1.29) ml kg(-1) min(-1), 56.86 (10.05) min, respectively].","Influence of acute normovolaemic haemodilution on the dose-response relationship, time-course of action and pharmacokinetics of rocuronium bromide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16873389/),min,56.86,73847,DB00728,Rocuronium
,27088998,Peak plasma concentrations,Peak plasma concentrations were larger using the mucosal atomization device (median [range]: 1.9 [1.4-3.2] μg/mL) than the spray tube (1.1 [0.6-2.0] μg/mL; P = 0.0021).,The Pharmacokinetics of Atomized Lidocaine Administered via the Trachea: A Randomized Trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27088998/),[μg] / [ml],1.9,75318,DB00728,Rocuronium
,27088998,Peak plasma concentrations,Peak plasma concentrations were larger using the mucosal atomization device (median [range]: 1.9 [1.4-3.2] μg/mL) than the spray tube (1.1 [0.6-2.0] μg/mL; P = 0.0021).,The Pharmacokinetics of Atomized Lidocaine Administered via the Trachea: A Randomized Trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27088998/),[μg] / [ml],1.1,75319,DB00728,Rocuronium
,27088998,bioavailability,"Our pharmacokinetic model estimated a difference of bioavailability between the atomized and the nonatomized lidocaine (0.801 and 0.559 respectively, P = 0.0005), whereas our model estimated no difference in the absorption rate constant (0.00688/min).",The Pharmacokinetics of Atomized Lidocaine Administered via the Trachea: A Randomized Trial. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27088998/),,0.801,75320,DB00728,Rocuronium
,27088998,bioavailability,"Our pharmacokinetic model estimated a difference of bioavailability between the atomized and the nonatomized lidocaine (0.801 and 0.559 respectively, P = 0.0005), whereas our model estimated no difference in the absorption rate constant (0.00688/min).",The Pharmacokinetics of Atomized Lidocaine Administered via the Trachea: A Randomized Trial. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27088998/),,0.559,75321,DB00728,Rocuronium
,27088998,absorption rate constant,"Our pharmacokinetic model estimated a difference of bioavailability between the atomized and the nonatomized lidocaine (0.801 and 0.559 respectively, P = 0.0005), whereas our model estimated no difference in the absorption rate constant (0.00688/min).",The Pharmacokinetics of Atomized Lidocaine Administered via the Trachea: A Randomized Trial. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27088998/),1/[min],0.00688,75322,DB00728,Rocuronium
,8557005,Onset time for maximum block,"Onset time for maximum block and duration of clinical relaxation (DUR25) were 61 (SD 25.0) s and 65 (16.4) s, 55 (26.9) min and 42 (9.3) min, respectively, for patients with and without renal failure.",Pharmacokinetics of rocuronium bromide in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557005/),s,61,76032,DB00728,Rocuronium
,8557005,duration of clinical relaxation (DUR25),"Onset time for maximum block and duration of clinical relaxation (DUR25) were 61 (SD 25.0) s and 65 (16.4) s, 55 (26.9) min and 42 (9.3) min, respectively, for patients with and without renal failure.",Pharmacokinetics of rocuronium bromide in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557005/),s,65,76033,DB00728,Rocuronium
,8557005,duration of clinical relaxation (DUR25),"Onset time for maximum block and duration of clinical relaxation (DUR25) were 61 (SD 25.0) s and 65 (16.4) s, 55 (26.9) min and 42 (9.3) min, respectively, for patients with and without renal failure.",Pharmacokinetics of rocuronium bromide in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557005/),min,42,76034,DB00728,Rocuronium
,8557005,time for,"The time for train-of-four ratio to return spontaneously to 0.7 was 99 (41.1) min and 73 (24.2) min, respectively, in the two groups.",Pharmacokinetics of rocuronium bromide in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557005/),min,0,76035,DB00728,Rocuronium
,8557005,time for,"The time for train-of-four ratio to return spontaneously to 0.7 was 99 (41.1) min and 73 (24.2) min, respectively, in the two groups.",Pharmacokinetics of rocuronium bromide in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557005/),min,99,76036,DB00728,Rocuronium
,8557005,time for,"The time for train-of-four ratio to return spontaneously to 0.7 was 99 (41.1) min and 73 (24.2) min, respectively, in the two groups.",Pharmacokinetics of rocuronium bromide in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557005/),min,73,76037,DB00728,Rocuronium
,8557005,train-of-four ratio to return spontaneously,"The time for train-of-four ratio to return spontaneously to 0.7 was 99 (41.1) min and 73 (24.2) min, respectively, in the two groups.",Pharmacokinetics of rocuronium bromide in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557005/),min,0,76038,DB00728,Rocuronium
,8557005,train-of-four ratio to return spontaneously,"The time for train-of-four ratio to return spontaneously to 0.7 was 99 (41.1) min and 73 (24.2) min, respectively, in the two groups.",Pharmacokinetics of rocuronium bromide in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557005/),min,99,76039,DB00728,Rocuronium
,8557005,train-of-four ratio to return spontaneously,"The time for train-of-four ratio to return spontaneously to 0.7 was 99 (41.1) min and 73 (24.2) min, respectively, in the two groups.",Pharmacokinetics of rocuronium bromide in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557005/),min,73,76040,DB00728,Rocuronium
,8557005,rates of clearance,"There were significant differences between patients with and without renal failure in the rates of clearance (2.5 (1.1) mL kg-1 min-1 and 3.7 (1.4) mL kg-1 min-1, respectively) and the mean residence times (97.1 (48.7) min and 58.3 (9.6) min) (P < 0.05).",Pharmacokinetics of rocuronium bromide in patients with and without renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557005/),[ml] / [kg·min],2.5,76041,DB00728,Rocuronium
,8557005,rates of clearance,"There were significant differences between patients with and without renal failure in the rates of clearance (2.5 (1.1) mL kg-1 min-1 and 3.7 (1.4) mL kg-1 min-1, respectively) and the mean residence times (97.1 (48.7) min and 58.3 (9.6) min) (P < 0.05).",Pharmacokinetics of rocuronium bromide in patients with and without renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557005/),[ml] / [kg·min],3.7,76042,DB00728,Rocuronium
,8557005,mean residence times,"There were significant differences between patients with and without renal failure in the rates of clearance (2.5 (1.1) mL kg-1 min-1 and 3.7 (1.4) mL kg-1 min-1, respectively) and the mean residence times (97.1 (48.7) min and 58.3 (9.6) min) (P < 0.05).",Pharmacokinetics of rocuronium bromide in patients with and without renal failure. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557005/),min,97.1,76043,DB00728,Rocuronium
,8557005,mean residence times,"There were significant differences between patients with and without renal failure in the rates of clearance (2.5 (1.1) mL kg-1 min-1 and 3.7 (1.4) mL kg-1 min-1, respectively) and the mean residence times (97.1 (48.7) min and 58.3 (9.6) min) (P < 0.05).",Pharmacokinetics of rocuronium bromide in patients with and without renal failure. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557005/),min,58.3,76044,DB00728,Rocuronium
,30099599,Ke0,Ke0 values ranged between 0.0820 and 0.247 depending on the pharmacokinetic model.,Rocuronium pharmacodynamic models for published five pharmacokinetic models: age and sex are covariates in pharmacodynamic models. ,Km-Q52,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30099599/),,0.0820,79759,DB00728,Rocuronium
,30099599,Ke0,Ke0 values ranged between 0.0820 and 0.247 depending on the pharmacokinetic model.,Rocuronium pharmacodynamic models for published five pharmacokinetic models: age and sex are covariates in pharmacodynamic models. ,Km-Q52,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30099599/),,0.247,79760,DB00728,Rocuronium
,28409297,total clearance,"Patients genotyped as -A or AA (n = 17) for SLCO1A2 -189_-188InsA showed reduced total clearance of ROC compared to patients genotyped as -/- (n = 13) (151.6 vs 207.1 mL/min, p ≤ 0.05).",The SLCO1A2 -189_-188InsA polymorphism reduces clearance of rocuronium in patients submitted to elective surgeries. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28409297/),[ml] / [min],151.6,81266,DB00728,Rocuronium
,28409297,total clearance,"Patients genotyped as -A or AA (n = 17) for SLCO1A2 -189_-188InsA showed reduced total clearance of ROC compared to patients genotyped as -/- (n = 13) (151.6 vs 207.1 mL/min, p ≤ 0.05).",The SLCO1A2 -189_-188InsA polymorphism reduces clearance of rocuronium in patients submitted to elective surgeries. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28409297/),[ml] / [min],207.1,81267,DB00728,Rocuronium
,28102538,clearance,The ROC clearance for HBD was significantly lower than that for LD (0.147 ± 0.052 vs. 0.265 ± 0.148 ml·min-1 ·g-1 liver) after intravenous injection (0.6 mg·kg-1 ).,Comparing early liver graft function from heart beating and living-donors: A pilot study aiming to identify new biomarkers of liver injury. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28102538/),[liver·ml] / [g·min],0.147,92727,DB00728,Rocuronium
,28102538,clearance,The ROC clearance for HBD was significantly lower than that for LD (0.147 ± 0.052 vs. 0.265 ± 0.148 ml·min-1 ·g-1 liver) after intravenous injection (0.6 mg·kg-1 ).,Comparing early liver graft function from heart beating and living-donors: A pilot study aiming to identify new biomarkers of liver injury. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28102538/),[liver·ml] / [g·min],0.265,92728,DB00728,Rocuronium
,28102538,clearance,"The clearance of TXA, a compound cleared by glomerular filtration, given as a 1 g bolus followed by infusion (10 mg·kg-1 ·h-1 ), was similar between HBD and LD groups (~ 1 ml·min-1 ·kg-1 ).",Comparing early liver graft function from heart beating and living-donors: A pilot study aiming to identify new biomarkers of liver injury. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28102538/),[ml] / [kg·min],1,92729,DB00728,Rocuronium
,8624003,ED50,ED50 of the initial dose was 144 micrograms.,Repeated doses of rocuronium bromide administered to cirrhotic and control patients receiving isoflurane. A clinical and pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8624003/),μg,144,96082,DB00728,Rocuronium
,8624003,initial volume of distribution,"kg-1 in control subjects, related to a higher initial volume of distribution (cirrhotic 78.5 +/- 31.7 ml.kg-1, control 29.8 +/- 17.3 ml.kg-1).",Repeated doses of rocuronium bromide administered to cirrhotic and control patients receiving isoflurane. A clinical and pharmacokinetic study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8624003/),[ml] / [kg],78.5,96083,DB00728,Rocuronium
,8624003,initial volume of distribution,"kg-1 in control subjects, related to a higher initial volume of distribution (cirrhotic 78.5 +/- 31.7 ml.kg-1, control 29.8 +/- 17.3 ml.kg-1).",Repeated doses of rocuronium bromide administered to cirrhotic and control patients receiving isoflurane. A clinical and pharmacokinetic study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8624003/),[ml] / [kg],29.8,96084,DB00728,Rocuronium
,8624003,Time from complementary dose to 25% recovery,"Time from complementary dose to 25% recovery was longer in cirrhotic patients (41.0 +/- 20.7 min vs 30.2 +/- 9.7 min), but time course of action during maintenance was not statistically different in the two groups.",Repeated doses of rocuronium bromide administered to cirrhotic and control patients receiving isoflurane. A clinical and pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8624003/),min,41.0,96085,DB00728,Rocuronium
,8624003,Time from complementary dose to 25% recovery,"Time from complementary dose to 25% recovery was longer in cirrhotic patients (41.0 +/- 20.7 min vs 30.2 +/- 9.7 min), but time course of action during maintenance was not statistically different in the two groups.",Repeated doses of rocuronium bromide administered to cirrhotic and control patients receiving isoflurane. A clinical and pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8624003/),min,30.2,96086,DB00728,Rocuronium
,8624003,volume of distribution at steady-state,"Spontaneous recovery was delayed in cirrhotic patients, because of impaired elimination processes: greater volume of distribution at steady-state (264 +/- 92 vs. 151 +/- 59 ml.kg-1); trend toward a lower clearance (189 +/- 60 vs. 296 +/- 169 ml.min-1).",Repeated doses of rocuronium bromide administered to cirrhotic and control patients receiving isoflurane. A clinical and pharmacokinetic study. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8624003/),[ml] / [kg],264,96087,DB00728,Rocuronium
,8624003,volume of distribution at steady-state,"Spontaneous recovery was delayed in cirrhotic patients, because of impaired elimination processes: greater volume of distribution at steady-state (264 +/- 92 vs. 151 +/- 59 ml.kg-1); trend toward a lower clearance (189 +/- 60 vs. 296 +/- 169 ml.min-1).",Repeated doses of rocuronium bromide administered to cirrhotic and control patients receiving isoflurane. A clinical and pharmacokinetic study. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8624003/),[ml] / [kg],151,96088,DB00728,Rocuronium
,8624003,clearance,"Spontaneous recovery was delayed in cirrhotic patients, because of impaired elimination processes: greater volume of distribution at steady-state (264 +/- 92 vs. 151 +/- 59 ml.kg-1); trend toward a lower clearance (189 +/- 60 vs. 296 +/- 169 ml.min-1).",Repeated doses of rocuronium bromide administered to cirrhotic and control patients receiving isoflurane. A clinical and pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8624003/),[ml] / [min],189,96089,DB00728,Rocuronium
,8624003,clearance,"Spontaneous recovery was delayed in cirrhotic patients, because of impaired elimination processes: greater volume of distribution at steady-state (264 +/- 92 vs. 151 +/- 59 ml.kg-1); trend toward a lower clearance (189 +/- 60 vs. 296 +/- 169 ml.min-1).",Repeated doses of rocuronium bromide administered to cirrhotic and control patients receiving isoflurane. A clinical and pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8624003/),[ml] / [min],296,96090,DB00728,Rocuronium
,19194156,recovery time,"After placebo, median recovery time of train-of-four to 0.9 was 21.0, 19.0, 23.4, and 28.5 min in infants, children, adolescents, and adults, respectively.",Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19194156/),min,21.0,98905,DB00728,Rocuronium
,19194156,recovery time,"After placebo, median recovery time of train-of-four to 0.9 was 21.0, 19.0, 23.4, and 28.5 min in infants, children, adolescents, and adults, respectively.",Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19194156/),min,19.0,98906,DB00728,Rocuronium
,19194156,recovery time,"After placebo, median recovery time of train-of-four to 0.9 was 21.0, 19.0, 23.4, and 28.5 min in infants, children, adolescents, and adults, respectively.",Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19194156/),min,23.4,98907,DB00728,Rocuronium
,19194156,recovery time,"After placebo, median recovery time of train-of-four to 0.9 was 21.0, 19.0, 23.4, and 28.5 min in infants, children, adolescents, and adults, respectively.",Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19194156/),min,28.5,98908,DB00728,Rocuronium
,19194156,train-of-four,"After 2.0 mg/kg sugammadex train-of-four 0.9 was attained in 0.6, 1.2, 1.1, and 1.2 min, respectively.",Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19194156/),min,0.9,98909,DB00728,Rocuronium
,19194156,train-of-four,"After 2.0 mg/kg sugammadex train-of-four 0.9 was attained in 0.6, 1.2, 1.1, and 1.2 min, respectively.",Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19194156/),min,0.6,98910,DB00728,Rocuronium
,19194156,train-of-four,"After 2.0 mg/kg sugammadex train-of-four 0.9 was attained in 0.6, 1.2, 1.1, and 1.2 min, respectively.",Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19194156/),min,1.2,98911,DB00728,Rocuronium
,19194156,train-of-four,"After 2.0 mg/kg sugammadex train-of-four 0.9 was attained in 0.6, 1.2, 1.1, and 1.2 min, respectively.",Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19194156/),min,1.1,98912,DB00728,Rocuronium
,19781381,effect-site concentration,"Anesthesia was induced with propofol, rocuronium and sufentanil administered by TCI lasting for 30 minutes, with target effect-site concentration of sufentanil 4 or 6 ng/ml.",Two-stage analysis of pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19781381/),[ng] / [ml],4,109705,DB00728,Rocuronium
,19781381,effect-site concentration,"Anesthesia was induced with propofol, rocuronium and sufentanil administered by TCI lasting for 30 minutes, with target effect-site concentration of sufentanil 4 or 6 ng/ml.",Two-stage analysis of pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19781381/),[ng] / [ml],6,109706,DB00728,Rocuronium
,19781381,volume of central compartment (V(1)),"The variables were derived as follows: the volume of central compartment (V(1)) was 5.4 L, volume of distribution at steady-state (Vdss) was 222.6 L, metabolic clearance (Cl(1)) was 0.84 L/min and elimination half-life (t(1/2Y)) was 389 minutes.",Two-stage analysis of pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19781381/),l,5.4,109707,DB00728,Rocuronium
,19781381,volume of distribution at steady-state (Vdss),"The variables were derived as follows: the volume of central compartment (V(1)) was 5.4 L, volume of distribution at steady-state (Vdss) was 222.6 L, metabolic clearance (Cl(1)) was 0.84 L/min and elimination half-life (t(1/2Y)) was 389 minutes.",Two-stage analysis of pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19781381/),l,222.6,109708,DB00728,Rocuronium
,19781381,metabolic clearance (Cl(1)),"The variables were derived as follows: the volume of central compartment (V(1)) was 5.4 L, volume of distribution at steady-state (Vdss) was 222.6 L, metabolic clearance (Cl(1)) was 0.84 L/min and elimination half-life (t(1/2Y)) was 389 minutes.",Two-stage analysis of pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese patients. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19781381/),[l] / [min],0.84,109709,DB00728,Rocuronium
,19781381,elimination half-life (t(1/2Y)),"The variables were derived as follows: the volume of central compartment (V(1)) was 5.4 L, volume of distribution at steady-state (Vdss) was 222.6 L, metabolic clearance (Cl(1)) was 0.84 L/min and elimination half-life (t(1/2Y)) was 389 minutes.",Two-stage analysis of pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19781381/),min,389,109710,DB00728,Rocuronium
,20007792,total plasma clearance (CL),Mean total plasma clearance (CL) of sugammadex was 5.5 ml min(-1) in renal patients and 95.2 ml min(-1) in controls (P<0.05).,Reduced clearance of rocuronium and sugammadex in patients with severe to end-stage renal failure: a pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20007792/),[ml] / [min],5.5,112482,DB00728,Rocuronium
,20007792,total plasma clearance (CL),Mean total plasma clearance (CL) of sugammadex was 5.5 ml min(-1) in renal patients and 95.2 ml min(-1) in controls (P<0.05).,Reduced clearance of rocuronium and sugammadex in patients with severe to end-stage renal failure: a pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20007792/),[ml] / [min],95.2,112483,DB00728,Rocuronium
,20007792,CL,Rocuronium CL was 41.8 ml min(-1) in renal patients and 167 ml min(-1) in controls (P<0.05).,Reduced clearance of rocuronium and sugammadex in patients with severe to end-stage renal failure: a pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20007792/),[ml] / [min],41.8,112484,DB00728,Rocuronium
,20007792,CL,Rocuronium CL was 41.8 ml min(-1) in renal patients and 167 ml min(-1) in controls (P<0.05).,Reduced clearance of rocuronium and sugammadex in patients with severe to end-stage renal failure: a pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20007792/),[ml] / [min],167,112485,DB00728,Rocuronium
,11094587,Urinary recovery,Urinary recovery within 48 h after administration was 26 (8)% (mean (SD)) (n = 8) of the dose.,"Urinary, biliary and faecal excretion of rocuronium in humans. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11094587/),%,26,117482,DB00728,Rocuronium
,11094587,recovery,"In bile obtained from T-drains, the recovery within 48 h was 7 (6)% (n = 11).","Urinary, biliary and faecal excretion of rocuronium in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11094587/),%,7,117483,DB00728,Rocuronium
,11094587,half-lives,"The rocuronium concentration in bile declined bi-exponentially, with half-lives of 2.3 (0.7) and 16 (11) h respectively (n = 6).","Urinary, biliary and faecal excretion of rocuronium in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11094587/),h,2.3,117484,DB00728,Rocuronium
,11094587,half-lives,"The rocuronium concentration in bile declined bi-exponentially, with half-lives of 2.3 (0.7) and 16 (11) h respectively (n = 6).","Urinary, biliary and faecal excretion of rocuronium in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11094587/),h,16,117485,DB00728,Rocuronium
,11094587,recovery,"In the second part of the study (Part B), urine and faeces were collected over 4-8 days and the recovery was 27 (13)% and 31 (23)% of the dose respectively (n = 10).","Urinary, biliary and faecal excretion of rocuronium in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11094587/),%,27,117486,DB00728,Rocuronium
,11094587,recovery,"In the second part of the study (Part B), urine and faeces were collected over 4-8 days and the recovery was 27 (13)% and 31 (23)% of the dose respectively (n = 10).","Urinary, biliary and faecal excretion of rocuronium in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11094587/),%,31,117487,DB00728,Rocuronium
,8557016,plasma clearance,"Hypothermia reduced the plasma clearance significantly (2.17 +/- 0.62 vs. 4.26 +/- 0.50 mL kg-1 min-1, P = 0.004), did not change the volume of distribution (224 +/- 64 vs. 232 +/- 60 mL kg-1 min-1, P = 1.0), and prolonged the mean residence time (108 +/- 39 vs. 56 +/- 19 mL kg-1 min-1, P = 0.01).",The influence of hypothermia (surface cooling) on the time-course of action and on the pharmacokinetics of rocuronium in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557016/),[ml] / [kg·min],2.17,128870,DB00728,Rocuronium
,8557016,plasma clearance,"Hypothermia reduced the plasma clearance significantly (2.17 +/- 0.62 vs. 4.26 +/- 0.50 mL kg-1 min-1, P = 0.004), did not change the volume of distribution (224 +/- 64 vs. 232 +/- 60 mL kg-1 min-1, P = 1.0), and prolonged the mean residence time (108 +/- 39 vs. 56 +/- 19 mL kg-1 min-1, P = 0.01).",The influence of hypothermia (surface cooling) on the time-course of action and on the pharmacokinetics of rocuronium in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557016/),[ml] / [kg·min],4.26,128871,DB00728,Rocuronium
,8557016,volume of distribution,"Hypothermia reduced the plasma clearance significantly (2.17 +/- 0.62 vs. 4.26 +/- 0.50 mL kg-1 min-1, P = 0.004), did not change the volume of distribution (224 +/- 64 vs. 232 +/- 60 mL kg-1 min-1, P = 1.0), and prolonged the mean residence time (108 +/- 39 vs. 56 +/- 19 mL kg-1 min-1, P = 0.01).",The influence of hypothermia (surface cooling) on the time-course of action and on the pharmacokinetics of rocuronium in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557016/),[ml] / [kg·min],224,128872,DB00728,Rocuronium
,8557016,volume of distribution,"Hypothermia reduced the plasma clearance significantly (2.17 +/- 0.62 vs. 4.26 +/- 0.50 mL kg-1 min-1, P = 0.004), did not change the volume of distribution (224 +/- 64 vs. 232 +/- 60 mL kg-1 min-1, P = 1.0), and prolonged the mean residence time (108 +/- 39 vs. 56 +/- 19 mL kg-1 min-1, P = 0.01).",The influence of hypothermia (surface cooling) on the time-course of action and on the pharmacokinetics of rocuronium in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557016/),[ml] / [kg·min],232,128873,DB00728,Rocuronium
,8557016,mean residence time,"Hypothermia reduced the plasma clearance significantly (2.17 +/- 0.62 vs. 4.26 +/- 0.50 mL kg-1 min-1, P = 0.004), did not change the volume of distribution (224 +/- 64 vs. 232 +/- 60 mL kg-1 min-1, P = 1.0), and prolonged the mean residence time (108 +/- 39 vs. 56 +/- 19 mL kg-1 min-1, P = 0.01).",The influence of hypothermia (surface cooling) on the time-course of action and on the pharmacokinetics of rocuronium in humans. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557016/),[ml] / [kg·min],108,128874,DB00728,Rocuronium
,8557016,mean residence time,"Hypothermia reduced the plasma clearance significantly (2.17 +/- 0.62 vs. 4.26 +/- 0.50 mL kg-1 min-1, P = 0.004), did not change the volume of distribution (224 +/- 64 vs. 232 +/- 60 mL kg-1 min-1, P = 1.0), and prolonged the mean residence time (108 +/- 39 vs. 56 +/- 19 mL kg-1 min-1, P = 0.01).",The influence of hypothermia (surface cooling) on the time-course of action and on the pharmacokinetics of rocuronium in humans. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557016/),[ml] / [kg·min],56,128875,DB00728,Rocuronium
,9366462,bioavailability,"With intramuscular administration, rocuronium's bioavailability averaged 82.6% and its absorption rate constant was 0.105 min(-1).",Bioavailability of intramuscular rocuronium in infants and children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9366462/),%,82.6,129967,DB00728,Rocuronium
,9366462,absorption rate constant,"With intramuscular administration, rocuronium's bioavailability averaged 82.6% and its absorption rate constant was 0.105 min(-1).",Bioavailability of intramuscular rocuronium in infants and children. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9366462/),1/[min],0.105,129968,DB00728,Rocuronium
,7925211,volume of distribution at steady state,"The pharmacokinetic parameters (volume of distribution at steady state, 309 +/- 80 ml kg-1, plasma clearance 4.5 +/- 1.96 ml kg-1 min-1, and elimination half-life 107 +/- 37 min) were similar to those previously reported after a large single bolus.",Pharmacodynamics and pharmacokinetics of rocuronium following continuous infusion in patients during intravenous anaesthesia. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7925211/),[ml] / [kg],309,132043,DB00728,Rocuronium
,7925211,plasma clearance,"The pharmacokinetic parameters (volume of distribution at steady state, 309 +/- 80 ml kg-1, plasma clearance 4.5 +/- 1.96 ml kg-1 min-1, and elimination half-life 107 +/- 37 min) were similar to those previously reported after a large single bolus.",Pharmacodynamics and pharmacokinetics of rocuronium following continuous infusion in patients during intravenous anaesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7925211/),[ml] / [kg·min],4.5,132044,DB00728,Rocuronium
,7925211,elimination half-life,"The pharmacokinetic parameters (volume of distribution at steady state, 309 +/- 80 ml kg-1, plasma clearance 4.5 +/- 1.96 ml kg-1 min-1, and elimination half-life 107 +/- 37 min) were similar to those previously reported after a large single bolus.",Pharmacodynamics and pharmacokinetics of rocuronium following continuous infusion in patients during intravenous anaesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7925211/),min,107,132045,DB00728,Rocuronium
,7925209,clearance,"Mean clearance was 5.2 ml kg-1 min-1, the terminal half-life was 69 min and distribution volume at steady state was 0.22 litre kg-1.",Pharmacokinetics and pharmacodynamics of rocuronium bromide in adult patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7925209/),[ml] / [kg·min],5.2,136530,DB00728,Rocuronium
,7925209,terminal half-life,"Mean clearance was 5.2 ml kg-1 min-1, the terminal half-life was 69 min and distribution volume at steady state was 0.22 litre kg-1.",Pharmacokinetics and pharmacodynamics of rocuronium bromide in adult patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7925209/),min,69,136531,DB00728,Rocuronium
,7925209,distribution volume at steady state,"Mean clearance was 5.2 ml kg-1 min-1, the terminal half-life was 69 min and distribution volume at steady state was 0.22 litre kg-1.",Pharmacokinetics and pharmacodynamics of rocuronium bromide in adult patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7925209/),[l] / [kg],0.22,136532,DB00728,Rocuronium
,7925209,Cumulative urinary excretion,Cumulative urinary excretion was around 18% within 24 h.,Pharmacokinetics and pharmacodynamics of rocuronium bromide in adult patients. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7925209/),%,18,136533,DB00728,Rocuronium
,27545305,Cl,"Elderly patients presented decreased Cl (2.1 ml/kg per min vs 2.8 ml/kg per min; P = 0.0123); increased AUC/dose (507.8 μg min/ml (mg/kg) vs 392.2 μg min/ml/(mg/kg); P = 0.0168) and reduced volume of distribution (285.4 ml/kg vs 435.6 ml/kg, P = 0.0434) compared to young adults.",Pharmacokinetics and pharmacodynamics of rocuronium in young adult and elderly patients undergoing elective surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27545305/),[ml] / [kg·min],2.1,152189,DB00728,Rocuronium
,27545305,Cl,"Elderly patients presented decreased Cl (2.1 ml/kg per min vs 2.8 ml/kg per min; P = 0.0123); increased AUC/dose (507.8 μg min/ml (mg/kg) vs 392.2 μg min/ml/(mg/kg); P = 0.0168) and reduced volume of distribution (285.4 ml/kg vs 435.6 ml/kg, P = 0.0434) compared to young adults.",Pharmacokinetics and pharmacodynamics of rocuronium in young adult and elderly patients undergoing elective surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27545305/),[ml] / [kg·min],2.8,152190,DB00728,Rocuronium
,27545305,AUC/dose,"Elderly patients presented decreased Cl (2.1 ml/kg per min vs 2.8 ml/kg per min; P = 0.0123); increased AUC/dose (507.8 μg min/ml (mg/kg) vs 392.2 μg min/ml/(mg/kg); P = 0.0168) and reduced volume of distribution (285.4 ml/kg vs 435.6 ml/kg, P = 0.0434) compared to young adults.",Pharmacokinetics and pharmacodynamics of rocuronium in young adult and elderly patients undergoing elective surgery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27545305/),[min·ml·μg] / [kg·mg],507.8,152191,DB00728,Rocuronium
,27545305,AUC/dose,"Elderly patients presented decreased Cl (2.1 ml/kg per min vs 2.8 ml/kg per min; P = 0.0123); increased AUC/dose (507.8 μg min/ml (mg/kg) vs 392.2 μg min/ml/(mg/kg); P = 0.0168) and reduced volume of distribution (285.4 ml/kg vs 435.6 ml/kg, P = 0.0434) compared to young adults.",Pharmacokinetics and pharmacodynamics of rocuronium in young adult and elderly patients undergoing elective surgery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27545305/),[min·ml·μg] / [kg·mg],392.2,152192,DB00728,Rocuronium
,27545305,volume of distribution,"Elderly patients presented decreased Cl (2.1 ml/kg per min vs 2.8 ml/kg per min; P = 0.0123); increased AUC/dose (507.8 μg min/ml (mg/kg) vs 392.2 μg min/ml/(mg/kg); P = 0.0168) and reduced volume of distribution (285.4 ml/kg vs 435.6 ml/kg, P = 0.0434) compared to young adults.",Pharmacokinetics and pharmacodynamics of rocuronium in young adult and elderly patients undergoing elective surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27545305/),[ml] / [kg],285.4,152193,DB00728,Rocuronium
,27545305,volume of distribution,"Elderly patients presented decreased Cl (2.1 ml/kg per min vs 2.8 ml/kg per min; P = 0.0123); increased AUC/dose (507.8 μg min/ml (mg/kg) vs 392.2 μg min/ml/(mg/kg); P = 0.0168) and reduced volume of distribution (285.4 ml/kg vs 435.6 ml/kg, P = 0.0434) compared to young adults.",Pharmacokinetics and pharmacodynamics of rocuronium in young adult and elderly patients undergoing elective surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27545305/),[ml] / [kg],435.6,152194,DB00728,Rocuronium
,27545305,concentrations required to achieve 50% of maximum neuromuscular block (EC50),The concentrations required to achieve 50% of maximum neuromuscular block (EC50) were similar for young adult (338.8 ng/ml) and elderly (462.7 ng/ml) patients (P > 0.05).,Pharmacokinetics and pharmacodynamics of rocuronium in young adult and elderly patients undergoing elective surgery. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27545305/),[ng] / [ml],338.8,152195,DB00728,Rocuronium
,27545305,concentrations required to achieve 50% of maximum neuromuscular block (EC50),The concentrations required to achieve 50% of maximum neuromuscular block (EC50) were similar for young adult (338.8 ng/ml) and elderly (462.7 ng/ml) patients (P > 0.05).,Pharmacokinetics and pharmacodynamics of rocuronium in young adult and elderly patients undergoing elective surgery. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27545305/),[ng] / [ml],462.7,152196,DB00728,Rocuronium
,21125318,diffusional time constant,Diffusion into the interstitial space determines the rate of rocuronium distribution in the body (diffusional time constant 89 min).,Circulatory model of vascular and interstitial distribution kinetics of rocuronium: a population analysis in patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21125318/),min,89,157244,DB00728,Rocuronium
,21125318,apparent permeability surface area product,The resulting whole body distribution kinetics depends both on cardiac output and on the apparent permeability surface area product (0.16 l/min).,Circulatory model of vascular and interstitial distribution kinetics of rocuronium: a population analysis in patients. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21125318/),[l] / [min],0.16,157245,DB00728,Rocuronium
,19236806,effect-site concentration,"Anesthetic induction was carried out with propofol, rocuronium and TCI administered sufentanil aiming for target effect-site concentration of sufentanil 4 or 6 ng/ml.",Pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese surgical patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19236806/),[ng] / [ml],4,158541,DB00728,Rocuronium
,19236806,effect-site concentration,"Anesthetic induction was carried out with propofol, rocuronium and TCI administered sufentanil aiming for target effect-site concentration of sufentanil 4 or 6 ng/ml.",Pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese surgical patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19236806/),[ng] / [ml],6,158542,DB00728,Rocuronium
,19236806,central volume of distribution (V(1)),"The pharmacokinetics of TCI administered sufentanil were optimally described by a three-compartment model with the following parameters: the central volume of distribution (V(1))=5.4 L, the volume of distribution at steady-state (Vdss)=195.4 L, systemic clearance (Cl(1))=1.10 L/min, and elimination half-life (t(1/2) gamma)=271.8 minutes.",Pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese surgical patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19236806/),l,5.4,158543,DB00728,Rocuronium
,19236806,volume of distribution at steady-state (Vdss),"The pharmacokinetics of TCI administered sufentanil were optimally described by a three-compartment model with the following parameters: the central volume of distribution (V(1))=5.4 L, the volume of distribution at steady-state (Vdss)=195.4 L, systemic clearance (Cl(1))=1.10 L/min, and elimination half-life (t(1/2) gamma)=271.8 minutes.",Pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese surgical patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19236806/),l,195.4,158544,DB00728,Rocuronium
,19236806,systemic clearance (Cl(1)),"The pharmacokinetics of TCI administered sufentanil were optimally described by a three-compartment model with the following parameters: the central volume of distribution (V(1))=5.4 L, the volume of distribution at steady-state (Vdss)=195.4 L, systemic clearance (Cl(1))=1.10 L/min, and elimination half-life (t(1/2) gamma)=271.8 minutes.",Pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese surgical patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19236806/),[l] / [min],1.10,158545,DB00728,Rocuronium
,19236806,elimination half-life (t(1/2) gamma),"The pharmacokinetics of TCI administered sufentanil were optimally described by a three-compartment model with the following parameters: the central volume of distribution (V(1))=5.4 L, the volume of distribution at steady-state (Vdss)=195.4 L, systemic clearance (Cl(1))=1.10 L/min, and elimination half-life (t(1/2) gamma)=271.8 minutes.",Pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese surgical patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19236806/),min,271.8,158546,DB00728,Rocuronium
,17681967,k(e0)s,"The k(e0)s obtained were 0.19 min(-1) (0.09-0.72) with the 't(peak)' method, 0.20 min(-1) (0.14-0.44) with the non-parametric method, and 0.19 min(-1) (0.11-0.38) [typical value (range)] with the parametric method (NS).",Estimation of the plasma effect-site equilibration rate constant (ke0) of rocuronium by the time of maximum effect: a comparison with non-parametric and parametric approaches. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17681967/),1/[min],0.19,160071,DB00728,Rocuronium
,17681967,k(e0)s,"The k(e0)s obtained were 0.19 min(-1) (0.09-0.72) with the 't(peak)' method, 0.20 min(-1) (0.14-0.44) with the non-parametric method, and 0.19 min(-1) (0.11-0.38) [typical value (range)] with the parametric method (NS).",Estimation of the plasma effect-site equilibration rate constant (ke0) of rocuronium by the time of maximum effect: a comparison with non-parametric and parametric approaches. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17681967/),1/[min],0.20,160072,DB00728,Rocuronium
,17681967,k(e0)s,"The k(e0)s obtained were 0.19 min(-1) (0.09-0.72) with the 't(peak)' method, 0.20 min(-1) (0.14-0.44) with the non-parametric method, and 0.19 min(-1) (0.11-0.38) [typical value (range)] with the parametric method (NS).",Estimation of the plasma effect-site equilibration rate constant (ke0) of rocuronium by the time of maximum effect: a comparison with non-parametric and parametric approaches. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17681967/),1/[min],0.19,160073,DB00728,Rocuronium
,7648768,half-life of transport,"The half-life of transport between plasma and biophase (effect compartment) was significantly shorter at the adductor laryngeal muscles (2.7 +/- 0.6 minutes, mean +/- SD) than at the adductor pollicis (4.4 +/- 1.5 minutes, p = 0.003).",Pharmacokinetics and pharmacodynamics of rocuronium at the vocal cords and the adductor pollicis in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7648768/),min,2.7,163533,DB00728,Rocuronium
,7648768,half-life of transport,"The half-life of transport between plasma and biophase (effect compartment) was significantly shorter at the adductor laryngeal muscles (2.7 +/- 0.6 minutes, mean +/- SD) than at the adductor pollicis (4.4 +/- 1.5 minutes, p = 0.003).",Pharmacokinetics and pharmacodynamics of rocuronium at the vocal cords and the adductor pollicis in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7648768/),min,4.4,163534,DB00728,Rocuronium
,8672375,onset time,"Mean onset time and time to recovery of T1 to 10% were 72 (SD 19.6) s and 27 (9.6) min, respectively.",Pharmacokinetics of rocuronium after bolus and continuous infusion during halothane anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8672375/),s,72,165500,DB00728,Rocuronium
,8672375,time to recovery,"Mean onset time and time to recovery of T1 to 10% were 72 (SD 19.6) s and 27 (9.6) min, respectively.",Pharmacokinetics of rocuronium after bolus and continuous infusion during halothane anaesthesia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8672375/),s,72,165501,DB00728,Rocuronium
,8672375,time to recovery,"Mean onset time and time to recovery of T1 to 10% were 72 (SD 19.6) s and 27 (9.6) min, respectively.",Pharmacokinetics of rocuronium after bolus and continuous infusion during halothane anaesthesia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8672375/),min,27,165502,DB00728,Rocuronium
,8672375,infusion rates,The infusion rates were stable in 19.8 (6.5) min.,Pharmacokinetics of rocuronium after bolus and continuous infusion during halothane anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8672375/),min,19.8,165503,DB00728,Rocuronium
,8672375,steady state 90% block of T1,The mean requirement for rocuronium for steady state 90% block of T1 was 528 (163.3) micrograms kg-1 h-1.,Pharmacokinetics of rocuronium after bolus and continuous infusion during halothane anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8672375/),[μg] / [h·kg],528,165504,DB00728,Rocuronium
,8672375,times to attain a,"The times to attain a T1 of 90% and a TOF ratio of 0.7 were 31 (11.7) min and 36 (7.3) min, respectively.",Pharmacokinetics of rocuronium after bolus and continuous infusion during halothane anaesthesia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8672375/),%,90,165505,DB00728,Rocuronium
,8672375,T1,"The times to attain a T1 of 90% and a TOF ratio of 0.7 were 31 (11.7) min and 36 (7.3) min, respectively.",Pharmacokinetics of rocuronium after bolus and continuous infusion during halothane anaesthesia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8672375/),%,90,165506,DB00728,Rocuronium
,8672375,TOF ratio,"The times to attain a T1 of 90% and a TOF ratio of 0.7 were 31 (11.7) min and 36 (7.3) min, respectively.",Pharmacokinetics of rocuronium after bolus and continuous infusion during halothane anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8672375/),min,0.7,165507,DB00728,Rocuronium
,8672375,TOF ratio,"The times to attain a T1 of 90% and a TOF ratio of 0.7 were 31 (11.7) min and 36 (7.3) min, respectively.",Pharmacokinetics of rocuronium after bolus and continuous infusion during halothane anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8672375/),min,31,165508,DB00728,Rocuronium
,8672375,TOF ratio,"The times to attain a T1 of 90% and a TOF ratio of 0.7 were 31 (11.7) min and 36 (7.3) min, respectively.",Pharmacokinetics of rocuronium after bolus and continuous infusion during halothane anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8672375/),min,36,165509,DB00728,Rocuronium
,8672375,rate of clearance,"The rate of clearance, mean residence time and volume of distribution at steady state were 3.3 (0.77) ml kg-1 min-1, 67.2 (18.8) min and 212.5 (40.1) ml kg-1, respectively.",Pharmacokinetics of rocuronium after bolus and continuous infusion during halothane anaesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8672375/),[ml] / [kg·min],3.3,165510,DB00728,Rocuronium
,8672375,mean residence time,"The rate of clearance, mean residence time and volume of distribution at steady state were 3.3 (0.77) ml kg-1 min-1, 67.2 (18.8) min and 212.5 (40.1) ml kg-1, respectively.",Pharmacokinetics of rocuronium after bolus and continuous infusion during halothane anaesthesia. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8672375/),min,67.2,165511,DB00728,Rocuronium
,8672375,volume of distribution at steady state,"The rate of clearance, mean residence time and volume of distribution at steady state were 3.3 (0.77) ml kg-1 min-1, 67.2 (18.8) min and 212.5 (40.1) ml kg-1, respectively.",Pharmacokinetics of rocuronium after bolus and continuous infusion during halothane anaesthesia. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8672375/),[ml] / [kg],212.5,165512,DB00728,Rocuronium
,8672375,distribution (T1/2 alpha),"The distribution (T1/2 alpha) and elimination (T1/2 beta) half-lives were 7.5 (3.33) min and 85.6 (18.4) min, respectively.",Pharmacokinetics of rocuronium after bolus and continuous infusion during halothane anaesthesia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8672375/),min,7.5,165513,DB00728,Rocuronium
,8672375,elimination (T1/2 beta) half-lives,"The distribution (T1/2 alpha) and elimination (T1/2 beta) half-lives were 7.5 (3.33) min and 85.6 (18.4) min, respectively.",Pharmacokinetics of rocuronium after bolus and continuous infusion during halothane anaesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8672375/),min,85.6,165514,DB00728,Rocuronium
,21535448,reversal times,"Simulated reversal times in typical adults were 0.8, 1.5 and 1.4 min upon reversal with sugammadex 16 mg kg(-1) 3 min after rocuronium, sugammadex 4 mg kg(-1) during deep neuromuscular blockade and sugammadex 2 mg kg(-1) during moderate blockade, respectively.",Population pharmacokinetic-pharmacodynamic analysis for sugammadex-mediated reversal of rocuronium-induced neuromuscular blockade. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21535448/),min,0.8,165601,DB00728,Rocuronium
,21535448,reversal times,"Simulated reversal times in typical adults were 0.8, 1.5 and 1.4 min upon reversal with sugammadex 16 mg kg(-1) 3 min after rocuronium, sugammadex 4 mg kg(-1) during deep neuromuscular blockade and sugammadex 2 mg kg(-1) during moderate blockade, respectively.",Population pharmacokinetic-pharmacodynamic analysis for sugammadex-mediated reversal of rocuronium-induced neuromuscular blockade. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21535448/),min,1.5,165602,DB00728,Rocuronium
,21535448,reversal times,"Simulated reversal times in typical adults were 0.8, 1.5 and 1.4 min upon reversal with sugammadex 16 mg kg(-1) 3 min after rocuronium, sugammadex 4 mg kg(-1) during deep neuromuscular blockade and sugammadex 2 mg kg(-1) during moderate blockade, respectively.",Population pharmacokinetic-pharmacodynamic analysis for sugammadex-mediated reversal of rocuronium-induced neuromuscular blockade. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21535448/),min,1.4,165603,DB00728,Rocuronium
<,21535448,reversal time,"Simulations of the therapeutic dosing regimens demonstrated limited impact of age, renal function and sevoflurane use, as predicted reversal time in typical subjects was always <2 min.",Population pharmacokinetic-pharmacodynamic analysis for sugammadex-mediated reversal of rocuronium-induced neuromuscular blockade. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21535448/),min,2,165604,DB00728,Rocuronium
,17457124,time to achieve a recovery of train-of-four ratio,The primary endpoint of the study was the time to achieve a recovery of train-of-four ratio to 0.9.,"Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17457124/),,0.9,177448,DB00728,Rocuronium
,17457124,time to recovery,"The mean time to recovery of the train-of-four ratio to 0.9 after dosing at 3, 5, and 15 min decreased from 52.1, 51.7, and 35.6 min, respectively, after administration of placebo to 1.8, 1.5, and 1.4 min, respectively, after 8 mg/kg sugammadex.","Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17457124/),min,0.9,177449,DB00728,Rocuronium
,17457124,time to recovery,"The mean time to recovery of the train-of-four ratio to 0.9 after dosing at 3, 5, and 15 min decreased from 52.1, 51.7, and 35.6 min, respectively, after administration of placebo to 1.8, 1.5, and 1.4 min, respectively, after 8 mg/kg sugammadex.","Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17457124/),min,52.1,177450,DB00728,Rocuronium
,17457124,time to recovery,"The mean time to recovery of the train-of-four ratio to 0.9 after dosing at 3, 5, and 15 min decreased from 52.1, 51.7, and 35.6 min, respectively, after administration of placebo to 1.8, 1.5, and 1.4 min, respectively, after 8 mg/kg sugammadex.","Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17457124/),min,51.7,177451,DB00728,Rocuronium
,17457124,time to recovery,"The mean time to recovery of the train-of-four ratio to 0.9 after dosing at 3, 5, and 15 min decreased from 52.1, 51.7, and 35.6 min, respectively, after administration of placebo to 1.8, 1.5, and 1.4 min, respectively, after 8 mg/kg sugammadex.","Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17457124/),min,35.6,177452,DB00728,Rocuronium
,17457124,time to recovery,"The mean time to recovery of the train-of-four ratio to 0.9 after dosing at 3, 5, and 15 min decreased from 52.1, 51.7, and 35.6 min, respectively, after administration of placebo to 1.8, 1.5, and 1.4 min, respectively, after 8 mg/kg sugammadex.","Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17457124/),min,1.8,177453,DB00728,Rocuronium
,17457124,time to recovery,"The mean time to recovery of the train-of-four ratio to 0.9 after dosing at 3, 5, and 15 min decreased from 52.1, 51.7, and 35.6 min, respectively, after administration of placebo to 1.8, 1.5, and 1.4 min, respectively, after 8 mg/kg sugammadex.","Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17457124/),min,1.5,177454,DB00728,Rocuronium
,17457124,time to recovery,"The mean time to recovery of the train-of-four ratio to 0.9 after dosing at 3, 5, and 15 min decreased from 52.1, 51.7, and 35.6 min, respectively, after administration of placebo to 1.8, 1.5, and 1.4 min, respectively, after 8 mg/kg sugammadex.","Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17457124/),min,1.4,177455,DB00728,Rocuronium
,17457124,cumulative excretion,The median cumulative excretion of rocuronium in the urine over 24 h was 26% in the placebo group and increased to 58-74% after 4-8 mg/kg sugammadex.,"Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17457124/),%,26,177456,DB00728,Rocuronium
,17457124,cumulative excretion,The median cumulative excretion of rocuronium in the urine over 24 h was 26% in the placebo group and increased to 58-74% after 4-8 mg/kg sugammadex.,"Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17457124/),%,58-74,177457,DB00728,Rocuronium
,17457124,plasma clearances,"The mean plasma clearances of sugammadex and rocuronium were 0.084 and 0.26 l/min, respectively.","Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17457124/),[l] / [min],0.084,177458,DB00728,Rocuronium
,17457124,plasma clearances,"The mean plasma clearances of sugammadex and rocuronium were 0.084 and 0.26 l/min, respectively.","Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17457124/),[l] / [min],0.26,177459,DB00728,Rocuronium
,16192761,association constant,"Org 25969 is a modified gamma-cyclodextrin that encapsulates the neuromuscular blocking agent, rocuronium bromide (Esmeron/Zemuron, NV Organon, Oss, The Netherlands), forming a tightly bound complex with an association constant of approximately 10 m.","First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16192761/),m,10,185760,DB00728,Rocuronium
,16192761,train-of-four ratio,"When 8 mg/kg Org 25969 was given, the train-of-four ratio returned to 0.9 within 2 min after its administration.","First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16192761/),,0.9,185761,DB00728,Rocuronium
,9449562,detection limits,The detection limits were 10 ng/ml for roc and 50 ng/ml for 17OH-roc.,Quantification of the neuromuscular blocking agent rocuronium and its putative metabolite 17-desacetylrocuronium in heparinized plasma by capillary gas chromatography using a nitrogen sensitive detector. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9449562/),[ng] / [ml],10,188474,DB00728,Rocuronium
,9449562,detection limits,The detection limits were 10 ng/ml for roc and 50 ng/ml for 17OH-roc.,Quantification of the neuromuscular blocking agent rocuronium and its putative metabolite 17-desacetylrocuronium in heparinized plasma by capillary gas chromatography using a nitrogen sensitive detector. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9449562/),[ng] / [ml],50,188475,DB00728,Rocuronium
,1443743,end-tidal concentrations,"All patients were anesthetized with nitrous oxide (50-70% in oxygen) and isoflurane (end-tidal concentrations of 1.2 +/- 0.5% and 0.8 +/- 0.2%, mean +/- SD, for control and transplant groups, respectively).",Pharmacokinetics of rocuronium bromide (ORG 9426) in patients with normal renal function or patients undergoing cadaver renal transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1443743/),,1,190405,DB00728,Rocuronium
,1443743,end-tidal concentrations,"All patients were anesthetized with nitrous oxide (50-70% in oxygen) and isoflurane (end-tidal concentrations of 1.2 +/- 0.5% and 0.8 +/- 0.2%, mean +/- SD, for control and transplant groups, respectively).",Pharmacokinetics of rocuronium bromide (ORG 9426) in patients with normal renal function or patients undergoing cadaver renal transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1443743/),%,0,190406,DB00728,Rocuronium
,1443743,Total plasma clearance,"Total plasma clearance (2.89 +/- 0.25 ml.kg-1.min-1, mean +/- SE) and volume of the central compartment (76.9 +/- 10.6 ml/kg) did not differ between control and renal transplant patients, whereas volume of distribution at steady state was greater in renal transplant patients (264 +/- 19 ml/kg) than in control patients (207 +/- 14 ml/kg).",Pharmacokinetics of rocuronium bromide (ORG 9426) in patients with normal renal function or patients undergoing cadaver renal transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1443743/),[ml] / [kg·min],2.89,190407,DB00728,Rocuronium
,1443743,volume of the central compartment,"Total plasma clearance (2.89 +/- 0.25 ml.kg-1.min-1, mean +/- SE) and volume of the central compartment (76.9 +/- 10.6 ml/kg) did not differ between control and renal transplant patients, whereas volume of distribution at steady state was greater in renal transplant patients (264 +/- 19 ml/kg) than in control patients (207 +/- 14 ml/kg).",Pharmacokinetics of rocuronium bromide (ORG 9426) in patients with normal renal function or patients undergoing cadaver renal transplantation. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1443743/),[ml] / [kg],76.9,190408,DB00728,Rocuronium
,1443743,volume of distribution at steady state,"Total plasma clearance (2.89 +/- 0.25 ml.kg-1.min-1, mean +/- SE) and volume of the central compartment (76.9 +/- 10.6 ml/kg) did not differ between control and renal transplant patients, whereas volume of distribution at steady state was greater in renal transplant patients (264 +/- 19 ml/kg) than in control patients (207 +/- 14 ml/kg).",Pharmacokinetics of rocuronium bromide (ORG 9426) in patients with normal renal function or patients undergoing cadaver renal transplantation. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1443743/),[ml] / [kg],264,190409,DB00728,Rocuronium
,1443743,volume of distribution at steady state,"Total plasma clearance (2.89 +/- 0.25 ml.kg-1.min-1, mean +/- SE) and volume of the central compartment (76.9 +/- 10.6 ml/kg) did not differ between control and renal transplant patients, whereas volume of distribution at steady state was greater in renal transplant patients (264 +/- 19 ml/kg) than in control patients (207 +/- 14 ml/kg).",Pharmacokinetics of rocuronium bromide (ORG 9426) in patients with normal renal function or patients undergoing cadaver renal transplantation. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1443743/),[ml] / [kg],207,190410,DB00728,Rocuronium
,1443743,elimination half life,This resulted in a longer elimination half life in renal transplant patients (97.2 +/- 17.3 min) compared to controls (70.9 +/- 4.7 min).,Pharmacokinetics of rocuronium bromide (ORG 9426) in patients with normal renal function or patients undergoing cadaver renal transplantation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1443743/),min,97.2,190411,DB00728,Rocuronium
,1443743,elimination half life,This resulted in a longer elimination half life in renal transplant patients (97.2 +/- 17.3 min) compared to controls (70.9 +/- 4.7 min).,Pharmacokinetics of rocuronium bromide (ORG 9426) in patients with normal renal function or patients undergoing cadaver renal transplantation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1443743/),min,70.9,190412,DB00728,Rocuronium
,12502989,EC50,Pharmacokinetic-pharmacodynamic analysis with the unbound receptor model demonstrated a decreased EC50 of 0.27 micro m (ranging from 0.17 to 0.59 micro m) compared to 2.71 micro m (ranging from 2.42 to 4.43 micro m) in control animals.,Pharmacokinetic-pharmacodynamic modeling of rocuronium in case of a decreased number of acetylcholine receptors: a study in myasthenic pigs. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12502989/),μm,0.27,191359,DB00728,Rocuronium
,12502989,EC50,Pharmacokinetic-pharmacodynamic analysis with the unbound receptor model demonstrated a decreased EC50 of 0.27 micro m (ranging from 0.17 to 0.59 micro m) compared to 2.71 micro m (ranging from 2.42 to 4.43 micro m) in control animals.,Pharmacokinetic-pharmacodynamic modeling of rocuronium in case of a decreased number of acetylcholine receptors: a study in myasthenic pigs. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12502989/),μm,2.71,191360,DB00728,Rocuronium
,12818941,Maximum block,"Maximum block during TCI targets-1000, 1300, and 1600 ng/mL-was smaller in children in comparison with infants and adults.","Target-controlled infusion of rocuronium in infants, children, and adults: a comparison of the pharmacokinetic and pharmacodynamic relationship. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12818941/),[ng] / [ml],1000,191819,DB00728,Rocuronium
,12818941,Maximum block,"Maximum block during TCI targets-1000, 1300, and 1600 ng/mL-was smaller in children in comparison with infants and adults.","Target-controlled infusion of rocuronium in infants, children, and adults: a comparison of the pharmacokinetic and pharmacodynamic relationship. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12818941/),[ng] / [ml],1300,191820,DB00728,Rocuronium
,12818941,Maximum block,"Maximum block during TCI targets-1000, 1300, and 1600 ng/mL-was smaller in children in comparison with infants and adults.","Target-controlled infusion of rocuronium in infants, children, and adults: a comparison of the pharmacokinetic and pharmacodynamic relationship. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12818941/),[ng] / [ml],1600,191821,DB00728,Rocuronium
,12818941,concentration in the effect compartment associated with a 50% drug effect (EC(50)),The concentration in the effect compartment associated with a 50% drug effect (EC(50)) was significantly smaller in infants (mean [SD]) (652 [215] ng/mL) than in adults (954 [276] ng/mL) and was the largest in children (1200 [295] ng/mL).,"Target-controlled infusion of rocuronium in infants, children, and adults: a comparison of the pharmacokinetic and pharmacodynamic relationship. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12818941/),[ng] / [ml],652,191822,DB00728,Rocuronium
,12818941,concentration in the effect compartment associated with a 50% drug effect (EC(50)),The concentration in the effect compartment associated with a 50% drug effect (EC(50)) was significantly smaller in infants (mean [SD]) (652 [215] ng/mL) than in adults (954 [276] ng/mL) and was the largest in children (1200 [295] ng/mL).,"Target-controlled infusion of rocuronium in infants, children, and adults: a comparison of the pharmacokinetic and pharmacodynamic relationship. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12818941/),[ng] / [ml],954,191823,DB00728,Rocuronium
,12818941,concentration in the effect compartment associated with a 50% drug effect (EC(50)),The concentration in the effect compartment associated with a 50% drug effect (EC(50)) was significantly smaller in infants (mean [SD]) (652 [215] ng/mL) than in adults (954 [276] ng/mL) and was the largest in children (1200 [295] ng/mL).,"Target-controlled infusion of rocuronium in infants, children, and adults: a comparison of the pharmacokinetic and pharmacodynamic relationship. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12818941/),[ng] / [ml],1200,191824,DB00728,Rocuronium
,12818941,EC(90),"Calculated mean EC(90) values were 1705, 2230, and 2035 ng/mL, respectively, in infants, children, and adults.","Target-controlled infusion of rocuronium in infants, children, and adults: a comparison of the pharmacokinetic and pharmacodynamic relationship. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12818941/),[ng] / [ml],1705,191825,DB00728,Rocuronium
,12818941,EC(90),"Calculated mean EC(90) values were 1705, 2230, and 2035 ng/mL, respectively, in infants, children, and adults.","Target-controlled infusion of rocuronium in infants, children, and adults: a comparison of the pharmacokinetic and pharmacodynamic relationship. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12818941/),[ng] / [ml],2230,191826,DB00728,Rocuronium
,12818941,EC(90),"Calculated mean EC(90) values were 1705, 2230, and 2035 ng/mL, respectively, in infants, children, and adults.","Target-controlled infusion of rocuronium in infants, children, and adults: a comparison of the pharmacokinetic and pharmacodynamic relationship. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12818941/),[ng] / [ml],2035,191827,DB00728,Rocuronium
,1829656,Onset time until maximum block,"Onset time until maximum block, duration until 25% recovery of twitch height, and recovery from 25 until 75% of twitch height were 1.7 (32), 53 (19) and 20 (37) min, respectively.","The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1829656/),min,1.7,197004,DB00728,Rocuronium
,1829656,duration until,"Onset time until maximum block, duration until 25% recovery of twitch height, and recovery from 25 until 75% of twitch height were 1.7 (32), 53 (19) and 20 (37) min, respectively.","The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1829656/),min,53,197005,DB00728,Rocuronium
,1829656,Half lives,"Half lives were 1.8 (33), 19 (34), 131 (62) min, respectively, in a three exponential decay; distribution volume at steady-state and plasma clearance were 0.264 (56) L.kg-1 and 4.0 (21) ml.kg-1.min-1, respectively.","The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1829656/),min,1.8,197006,DB00728,Rocuronium
,1829656,Half lives,"Half lives were 1.8 (33), 19 (34), 131 (62) min, respectively, in a three exponential decay; distribution volume at steady-state and plasma clearance were 0.264 (56) L.kg-1 and 4.0 (21) ml.kg-1.min-1, respectively.","The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1829656/),min,19,197007,DB00728,Rocuronium
,1829656,Half lives,"Half lives were 1.8 (33), 19 (34), 131 (62) min, respectively, in a three exponential decay; distribution volume at steady-state and plasma clearance were 0.264 (56) L.kg-1 and 4.0 (21) ml.kg-1.min-1, respectively.","The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1829656/),min,131,197008,DB00728,Rocuronium
,1829656,distribution volume at steady-state,"Half lives were 1.8 (33), 19 (34), 131 (62) min, respectively, in a three exponential decay; distribution volume at steady-state and plasma clearance were 0.264 (56) L.kg-1 and 4.0 (21) ml.kg-1.min-1, respectively.","The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1829656/),[l] / [kg],0.264,197009,DB00728,Rocuronium
,1829656,plasma clearance,"Half lives were 1.8 (33), 19 (34), 131 (62) min, respectively, in a three exponential decay; distribution volume at steady-state and plasma clearance were 0.264 (56) L.kg-1 and 4.0 (21) ml.kg-1.min-1, respectively.","The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1829656/),[ml] / [kg·min],4.0,197010,DB00728,Rocuronium
,1829656,Plasma concentration at 25% recovery of the twitch height,Plasma concentration at 25% recovery of the twitch height was 1.0 mg.L-1.,"The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1829656/),[mg] / [l],1.0,197011,DB00728,Rocuronium
,7739943,Plasma clearance,Plasma clearance was greater during isoflurane than during balanced anesthesia (4.48 vs 3.49 ml/kg/min).,The effect of isoflurane versus balanced anesthesia on rocuronium's pharmacokinetics and infusion requirement. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7739943/),[ml] / [kg·min],4.48,199576,DB00728,Rocuronium
,7739943,Plasma clearance,Plasma clearance was greater during isoflurane than during balanced anesthesia (4.48 vs 3.49 ml/kg/min).,The effect of isoflurane versus balanced anesthesia on rocuronium's pharmacokinetics and infusion requirement. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7739943/),[ml] / [kg·min],3.49,199577,DB00728,Rocuronium
,19690247,duration of action,"The median (range) duration of action was 32 (18-49), 38 (25-66), and 42 (24-66) min in the IBW, CBW20%, and CBW40% groups, respectively (P = 0.001 for comparison of the IBW and CBW40% group).",Should dosing of rocuronium in obese patients be based on ideal or corrected body weight? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19690247/),min,32,204201,DB00728,Rocuronium
,19690247,duration of action,"The median (range) duration of action was 32 (18-49), 38 (25-66), and 42 (24-66) min in the IBW, CBW20%, and CBW40% groups, respectively (P = 0.001 for comparison of the IBW and CBW40% group).",Should dosing of rocuronium in obese patients be based on ideal or corrected body weight? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19690247/),min,38,204202,DB00728,Rocuronium
,19690247,duration of action,"The median (range) duration of action was 32 (18-49), 38 (25-66), and 42 (24-66) min in the IBW, CBW20%, and CBW40% groups, respectively (P = 0.001 for comparison of the IBW and CBW40% group).",Should dosing of rocuronium in obese patients be based on ideal or corrected body weight? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19690247/),min,42,204203,DB00728,Rocuronium
,19690247,onset time,There were no significant differences in onset time (85 vs 84 vs 80 s) or in intubation conditions 90 s after administration of rocuronium.,Should dosing of rocuronium in obese patients be based on ideal or corrected body weight? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19690247/),s,85,204204,DB00728,Rocuronium
,19690247,onset time,There were no significant differences in onset time (85 vs 84 vs 80 s) or in intubation conditions 90 s after administration of rocuronium.,Should dosing of rocuronium in obese patients be based on ideal or corrected body weight? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19690247/),s,84,204205,DB00728,Rocuronium
,19690247,onset time,There were no significant differences in onset time (85 vs 84 vs 80 s) or in intubation conditions 90 s after administration of rocuronium.,Should dosing of rocuronium in obese patients be based on ideal or corrected body weight? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19690247/),s,80,204206,DB00728,Rocuronium
,18521585,total plasma clearance,The CPT therapy was found to increase the total plasma clearance from 0.26 to 0.75 L min(-1).,Pharmacokinetic-pharmacodynamic modeling of the influence of chronic phenytoin therapy on the rocuronium bromide response in patients undergoing brain surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18521585/),[l] / [min],0.26,205526,DB00728,Rocuronium
,18521585,total plasma clearance,The CPT therapy was found to increase the total plasma clearance from 0.26 to 0.75 L min(-1).,Pharmacokinetic-pharmacodynamic modeling of the influence of chronic phenytoin therapy on the rocuronium bromide response in patients undergoing brain surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18521585/),[l] / [min],0.75,205527,DB00728,Rocuronium
,18521585,k(e0),"The PD model parameter estimates were k(e0)= 0.073 min(-1), IC(50) (the steady-state plasma concentration eliciting half of the maximum response) = 836 ng mL(-1) and gamma = 3.13.",Pharmacokinetic-pharmacodynamic modeling of the influence of chronic phenytoin therapy on the rocuronium bromide response in patients undergoing brain surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18521585/),1/[min],0.073,205528,DB00728,Rocuronium
,18521585,IC(50) (the,"The PD model parameter estimates were k(e0)= 0.073 min(-1), IC(50) (the steady-state plasma concentration eliciting half of the maximum response) = 836 ng mL(-1) and gamma = 3.13.",Pharmacokinetic-pharmacodynamic modeling of the influence of chronic phenytoin therapy on the rocuronium bromide response in patients undergoing brain surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18521585/),[ng] / [ml],836,205529,DB00728,Rocuronium
,18521585,steady-state plasma concentration eliciting half of the maximum response),"The PD model parameter estimates were k(e0)= 0.073 min(-1), IC(50) (the steady-state plasma concentration eliciting half of the maximum response) = 836 ng mL(-1) and gamma = 3.13.",Pharmacokinetic-pharmacodynamic modeling of the influence of chronic phenytoin therapy on the rocuronium bromide response in patients undergoing brain surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18521585/),[ng] / [ml],836,205530,DB00728,Rocuronium
,18521585,gamma,"The PD model parameter estimates were k(e0)= 0.073 min(-1), IC(50) (the steady-state plasma concentration eliciting half of the maximum response) = 836 ng mL(-1) and gamma = 3.13.",Pharmacokinetic-pharmacodynamic modeling of the influence of chronic phenytoin therapy on the rocuronium bromide response in patients undergoing brain surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18521585/),,3.13,205531,DB00728,Rocuronium
,18521585,clearance,"Chronic phenytoin therapy increases the clearance of rocuronium from 0.26 to 0.75 L min(-1) but has no effect on the k(e0), IC(50) or gamma parameters.",Pharmacokinetic-pharmacodynamic modeling of the influence of chronic phenytoin therapy on the rocuronium bromide response in patients undergoing brain surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18521585/),[l] / [min],0.26,205532,DB00728,Rocuronium
,20308820,recovery rate,The recovery rate of the in vitro assay was 36% at a pump rate of 1 microL/min.,Feasibility of microdialysis to determine interstitial rocuronium concentration in the muscle tissue of anesthetized neurosurgical patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20308820/),%,36,206740,DB00728,Rocuronium
,20308820,pump rate,The recovery rate of the in vitro assay was 36% at a pump rate of 1 microL/min.,Feasibility of microdialysis to determine interstitial rocuronium concentration in the muscle tissue of anesthetized neurosurgical patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20308820/),[μl] / [min],1,206741,DB00728,Rocuronium
,8010470,onset of neuromuscular blockade,The onset of neuromuscular blockade was longer (P < 0.01) in patients with cirrhosis (158 +/- 56 s) than in normal patients (108 +/- 33 s).,Pharmacokinetics and pharmacodynamics of rocuronium in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010470/),s,158,213175,DB00728,Rocuronium
,8010470,onset of neuromuscular blockade,The onset of neuromuscular blockade was longer (P < 0.01) in patients with cirrhosis (158 +/- 56 s) than in normal patients (108 +/- 33 s).,Pharmacokinetics and pharmacodynamics of rocuronium in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010470/),s,108,213176,DB00728,Rocuronium
,8010470,Recovery of the,"Recovery of the thumb twitch to 75 and 90% of its control value was 77 +/- 25 and 88 +/- 29 min in cirrhotic patients versus 57 +/- 11 and 64 +/- 13 min, respectively, in normal patients (P < 0.05).",Pharmacokinetics and pharmacodynamics of rocuronium in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010470/),min,77,213177,DB00728,Rocuronium
,8010470,Recovery of the,"Recovery of the thumb twitch to 75 and 90% of its control value was 77 +/- 25 and 88 +/- 29 min in cirrhotic patients versus 57 +/- 11 and 64 +/- 13 min, respectively, in normal patients (P < 0.05).",Pharmacokinetics and pharmacodynamics of rocuronium in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010470/),min,88,213178,DB00728,Rocuronium
,8010470,Recovery of the,"Recovery of the thumb twitch to 75 and 90% of its control value was 77 +/- 25 and 88 +/- 29 min in cirrhotic patients versus 57 +/- 11 and 64 +/- 13 min, respectively, in normal patients (P < 0.05).",Pharmacokinetics and pharmacodynamics of rocuronium in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010470/),min,57,213179,DB00728,Rocuronium
,8010470,Recovery of the,"Recovery of the thumb twitch to 75 and 90% of its control value was 77 +/- 25 and 88 +/- 29 min in cirrhotic patients versus 57 +/- 11 and 64 +/- 13 min, respectively, in normal patients (P < 0.05).",Pharmacokinetics and pharmacodynamics of rocuronium in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010470/),min,64,213180,DB00728,Rocuronium
,8010470,central volume of distribution,The central volume of distribution of rocuronium was 104 +/- 21 in cirrhotic patients and 78 +/- 24 ml.kg-1 in normal patients (P < 0.05).,Pharmacokinetics and pharmacodynamics of rocuronium in patients with cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010470/),[ml] / [kg],104,213181,DB00728,Rocuronium
,8010470,central volume of distribution,The central volume of distribution of rocuronium was 104 +/- 21 in cirrhotic patients and 78 +/- 24 ml.kg-1 in normal patients (P < 0.05).,Pharmacokinetics and pharmacodynamics of rocuronium in patients with cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010470/),[ml] / [kg],78,213182,DB00728,Rocuronium
,8010470,elimination half-life,The elimination half-life was 87.5 +/- 17.5 min in normal patients and 96.0 +/- 36.8 min in cirrhotic patients (difference not significant).,Pharmacokinetics and pharmacodynamics of rocuronium in patients with cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010470/),min,87.5,213183,DB00728,Rocuronium
,8010470,elimination half-life,The elimination half-life was 87.5 +/- 17.5 min in normal patients and 96.0 +/- 36.8 min in cirrhotic patients (difference not significant).,Pharmacokinetics and pharmacodynamics of rocuronium in patients with cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010470/),min,96.0,213184,DB00728,Rocuronium
,19493418,effect-site concentration (Ce),"When an Observer's Assessment of Alertness/Sedation (OAA/S) score of 1 was achieved, remifentanil (effect-site concentration (Ce) of 4.0 ng/ml) and rocuronium 0.9 mg/kg were administered.",Relationship between depth of anesthesia and effect-site concentration of propofol during induction with the target-controlled infusion technique in elderly patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493418/),[ng] / [ml],4.0,218989,DB00728,Rocuronium
,19493418,Ce,"When an OAA/S score of 1 was achieved, Ce of propofol were (1.7 +/- 0.4) microg/ml, (1.9 +/- 0.3) microg/ml, (1.9 +/- 0.4) microg/ml and the BIS values were 64 +/- 5, 65 +/- 8, and 62 +/- 8 in Groups S1, S2 and S3.",Relationship between depth of anesthesia and effect-site concentration of propofol during induction with the target-controlled infusion technique in elderly patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493418/),[μg] / [ml],1.7,218990,DB00728,Rocuronium
,19493418,Ce,"When an OAA/S score of 1 was achieved, Ce of propofol were (1.7 +/- 0.4) microg/ml, (1.9 +/- 0.3) microg/ml, (1.9 +/- 0.4) microg/ml and the BIS values were 64 +/- 5, 65 +/- 8, and 62 +/- 8 in Groups S1, S2 and S3.",Relationship between depth of anesthesia and effect-site concentration of propofol during induction with the target-controlled infusion technique in elderly patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493418/),[μg] / [ml],1.9,218991,DB00728,Rocuronium
,19493418,Ce,"When an OAA/S score of 1 was achieved, Ce of propofol were (1.7 +/- 0.4) microg/ml, (1.9 +/- 0.3) microg/ml, (1.9 +/- 0.4) microg/ml and the BIS values were 64 +/- 5, 65 +/- 8, and 62 +/- 8 in Groups S1, S2 and S3.",Relationship between depth of anesthesia and effect-site concentration of propofol during induction with the target-controlled infusion technique in elderly patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493418/),[μg] / [ml],1.9,218992,DB00728,Rocuronium
,19493418,BIS,"When an OAA/S score of 1 was achieved, Ce of propofol were (1.7 +/- 0.4) microg/ml, (1.9 +/- 0.3) microg/ml, (1.9 +/- 0.4) microg/ml and the BIS values were 64 +/- 5, 65 +/- 8, and 62 +/- 8 in Groups S1, S2 and S3.",Relationship between depth of anesthesia and effect-site concentration of propofol during induction with the target-controlled infusion technique in elderly patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493418/),,64,218993,DB00728,Rocuronium
,19493418,BIS,"When an OAA/S score of 1 was achieved, Ce of propofol were (1.7 +/- 0.4) microg/ml, (1.9 +/- 0.3) microg/ml, (1.9 +/- 0.4) microg/ml and the BIS values were 64 +/- 5, 65 +/- 8, and 62 +/- 8 in Groups S1, S2 and S3.",Relationship between depth of anesthesia and effect-site concentration of propofol during induction with the target-controlled infusion technique in elderly patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493418/),,65,218994,DB00728,Rocuronium
,19493418,BIS,"When an OAA/S score of 1 was achieved, Ce of propofol were (1.7 +/- 0.4) microg/ml, (1.9 +/- 0.3) microg/ml, (1.9 +/- 0.4) microg/ml and the BIS values were 64 +/- 5, 65 +/- 8, and 62 +/- 8 in Groups S1, S2 and S3.",Relationship between depth of anesthesia and effect-site concentration of propofol during induction with the target-controlled infusion technique in elderly patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493418/),,62,218995,DB00728,Rocuronium
,19493418,Ce,"Before intubation, Ce of propofol was (2.8 +/- 0.2) microg/ml, (2.8 +/- 0.3) microg/ml, (2.7 +/- 0.3) microg/ml, and the BIS values were 48 +/- 7, 51 +/- 7, and 47 +/- 5 in Groups S1, S2 and S3.",Relationship between depth of anesthesia and effect-site concentration of propofol during induction with the target-controlled infusion technique in elderly patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493418/),[μg] / [ml],2.8,218996,DB00728,Rocuronium
,19493418,Ce,"Before intubation, Ce of propofol was (2.8 +/- 0.2) microg/ml, (2.8 +/- 0.3) microg/ml, (2.7 +/- 0.3) microg/ml, and the BIS values were 48 +/- 7, 51 +/- 7, and 47 +/- 5 in Groups S1, S2 and S3.",Relationship between depth of anesthesia and effect-site concentration of propofol during induction with the target-controlled infusion technique in elderly patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493418/),[μg] / [ml],2.8,218997,DB00728,Rocuronium
,19493418,Ce,"Before intubation, Ce of propofol was (2.8 +/- 0.2) microg/ml, (2.8 +/- 0.3) microg/ml, (2.7 +/- 0.3) microg/ml, and the BIS values were 48 +/- 7, 51 +/- 7, and 47 +/- 5 in Groups S1, S2 and S3.",Relationship between depth of anesthesia and effect-site concentration of propofol during induction with the target-controlled infusion technique in elderly patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493418/),[μg] / [ml],2.7,218998,DB00728,Rocuronium
,19493418,BIS,"Before intubation, Ce of propofol was (2.8 +/- 0.2) microg/ml, (2.8 +/- 0.3) microg/ml, (2.7 +/- 0.3) microg/ml, and the BIS values were 48 +/- 7, 51 +/- 7, and 47 +/- 5 in Groups S1, S2 and S3.",Relationship between depth of anesthesia and effect-site concentration of propofol during induction with the target-controlled infusion technique in elderly patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493418/),,48,218999,DB00728,Rocuronium
,19493418,BIS,"Before intubation, Ce of propofol was (2.8 +/- 0.2) microg/ml, (2.8 +/- 0.3) microg/ml, (2.7 +/- 0.3) microg/ml, and the BIS values were 48 +/- 7, 51 +/- 7, and 47 +/- 5 in Groups S1, S2 and S3.",Relationship between depth of anesthesia and effect-site concentration of propofol during induction with the target-controlled infusion technique in elderly patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493418/),,51,219000,DB00728,Rocuronium
,19493418,BIS,"Before intubation, Ce of propofol was (2.8 +/- 0.2) microg/ml, (2.8 +/- 0.3) microg/ml, (2.7 +/- 0.3) microg/ml, and the BIS values were 48 +/- 7, 51 +/- 7, and 47 +/- 5 in Groups S1, S2 and S3.",Relationship between depth of anesthesia and effect-site concentration of propofol during induction with the target-controlled infusion technique in elderly patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493418/),,47,219001,DB00728,Rocuronium
,19493418,Ce,"During the TCI induction, Ce of propofol with (1.9 +/- 0.3) microg/ml may make the elderly patients unconscious.",Relationship between depth of anesthesia and effect-site concentration of propofol during induction with the target-controlled infusion technique in elderly patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493418/),[μg] / [ml],1.9,219002,DB00728,Rocuronium
,19493418,Ce,When remifentanil with a Ce of 4.0 ng/ml is added a Ce of propofol with (2.8 +/- 0.3) microg/ml is suitable for intubation.,Relationship between depth of anesthesia and effect-site concentration of propofol during induction with the target-controlled infusion technique in elderly patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493418/),[ng] / [ml],4.0,219003,DB00728,Rocuronium
,19493418,Ce,When remifentanil with a Ce of 4.0 ng/ml is added a Ce of propofol with (2.8 +/- 0.3) microg/ml is suitable for intubation.,Relationship between depth of anesthesia and effect-site concentration of propofol during induction with the target-controlled infusion technique in elderly patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493418/),[μg] / [ml],2.8,219004,DB00728,Rocuronium
,25725779,r.c.,"The mean Rb r.c. was 1.56 ± 0.35 μg/ml, with minimum and maximum values of 1.09 and 2.08 μg/ml, respectively.",Effective method of continuous rocuronium administration based on effect-site concentrations using a pharmacokinetic/pharmacodynamic model during propofol-remifentanil anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25725779/),[μg] / [ml],1.56,224992,DB00728,Rocuronium
,25725779,minimum,"The mean Rb r.c. was 1.56 ± 0.35 μg/ml, with minimum and maximum values of 1.09 and 2.08 μg/ml, respectively.",Effective method of continuous rocuronium administration based on effect-site concentrations using a pharmacokinetic/pharmacodynamic model during propofol-remifentanil anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25725779/),[μg] / [ml],1.09,224993,DB00728,Rocuronium
,25725779,minimum,"The mean Rb r.c. was 1.56 ± 0.35 μg/ml, with minimum and maximum values of 1.09 and 2.08 μg/ml, respectively.",Effective method of continuous rocuronium administration based on effect-site concentrations using a pharmacokinetic/pharmacodynamic model during propofol-remifentanil anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25725779/),[μg] / [ml],2.08,224994,DB00728,Rocuronium
,25725779,maximum,"The mean Rb r.c. was 1.56 ± 0.35 μg/ml, with minimum and maximum values of 1.09 and 2.08 μg/ml, respectively.",Effective method of continuous rocuronium administration based on effect-site concentrations using a pharmacokinetic/pharmacodynamic model during propofol-remifentanil anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25725779/),[μg] / [ml],2.08,224995,DB00728,Rocuronium
,25725779,recovery period,"The %T1 did not increase above 10 % in any of the patients during continuous administration of Rb, and the recovery period to %T1 > 25 % ranged from 9 to 29 min.",Effective method of continuous rocuronium administration based on effect-site concentrations using a pharmacokinetic/pharmacodynamic model during propofol-remifentanil anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25725779/),min,9 to 29,224996,DB00728,Rocuronium
,21239968,time,"The geometric mean time (95% confidence interval) from sugammadex administration to recovery of the TOF ratio to 0.9 increased with age, from 2.3 (2.0-2.6) min (adults) to 2.9 (2.7-3.2) min (elderly/old-elderly groups combined).","Efficacy, safety, and pharmacokinetics of sugammadex for the reversal of rocuronium-induced neuromuscular blockade in elderly patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21239968/),min,2.3,227159,DB00728,Rocuronium
,21239968,time,"The geometric mean time (95% confidence interval) from sugammadex administration to recovery of the TOF ratio to 0.9 increased with age, from 2.3 (2.0-2.6) min (adults) to 2.9 (2.7-3.2) min (elderly/old-elderly groups combined).","Efficacy, safety, and pharmacokinetics of sugammadex for the reversal of rocuronium-induced neuromuscular blockade in elderly patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21239968/),min,2.9,227160,DB00728,Rocuronium
,21239968,Recovery of the TOF ratio,Recovery of the TOF ratio to 0.9 was estimated to be 0.7 min faster in adults compared with patients aged 65 yr or older (P = 0.022).,"Efficacy, safety, and pharmacokinetics of sugammadex for the reversal of rocuronium-induced neuromuscular blockade in elderly patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21239968/),,0.9,227161,DB00728,Rocuronium
,10223167,clearance,It has a low clearance (0.16 L/h/kg) and long elimination half-life (120 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),[l] / [h·kg],0.16,240354,DB00728,Rocuronium
,10223167,elimination half-life,It has a low clearance (0.16 L/h/kg) and long elimination half-life (120 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),min,120,240355,DB00728,Rocuronium
,10223167,clearance,"Its clearance (0.27 L/h/kg) is intermediate between those of pipecuronium and rapacuronium, but its elimination half-life is long (83 minutes).",Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),[l] / [h·kg],0.27,240356,DB00728,Rocuronium
,10223167,elimination half-life,"Its clearance (0.27 L/h/kg) is intermediate between those of pipecuronium and rapacuronium, but its elimination half-life is long (83 minutes).",Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),min,83,240357,DB00728,Rocuronium
,10223167,clearance,It has a high clearance (0.59 L/h/kg) but a long elimination half-life (112 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),[l] / [h·kg],0.59,240358,DB00728,Rocuronium
,10223167,elimination half-life,It has a high clearance (0.59 L/h/kg) but a long elimination half-life (112 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),min,112,240359,DB00728,Rocuronium
,10223167,clearance,"In adults, it has a low clearance (0.15 L/h/kg) and long elimination half-life (87 minutes).",Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),[l] / [h·kg],0.15,240360,DB00728,Rocuronium
,10223167,elimination half-life,"In adults, it has a low clearance (0.15 L/h/kg) and long elimination half-life (87 minutes).",Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),min,87,240361,DB00728,Rocuronium
,10223167,clearance,The 2 active isomers (cis-trans and trans-trans) have a high clearance (4.74 L/h/kg) and very short elimination half-lives (approximately 2 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),[l] / [h·kg],4.74,240362,DB00728,Rocuronium
,10223167,elimination half-lives,The 2 active isomers (cis-trans and trans-trans) have a high clearance (4.74 L/h/kg) and very short elimination half-lives (approximately 2 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),min,2,240363,DB00728,Rocuronium
,10223167,clearance,Cisatracurium has an intermediate clearance (0.3 L/h/kg) and short elimination half-life (26 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),[l] / [h·kg],0.3,240364,DB00728,Rocuronium
,10223167,elimination half-life,Cisatracurium has an intermediate clearance (0.3 L/h/kg) and short elimination half-life (26 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),min,26,240365,DB00728,Rocuronium
,8250312,plasma clearance,"Elderly patients, when compared with the younger, also exhibited a significant decrease in plasma clearance (3.67 +/- 1.0 vs 5.03 +/- 1.5 mL.kg-1.min-1, mean +/- SD) and volume of distribution (399 +/- 122 vs 553 +/- 279 mL/kg, mean +/- SD).",Pharmacokinetics and pharmacodynamics of rocuronium (Org 9426) in elderly surgical patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8250312/),[ml] / [kg·min],3.67,240566,DB00728,Rocuronium
,8250312,plasma clearance,"Elderly patients, when compared with the younger, also exhibited a significant decrease in plasma clearance (3.67 +/- 1.0 vs 5.03 +/- 1.5 mL.kg-1.min-1, mean +/- SD) and volume of distribution (399 +/- 122 vs 553 +/- 279 mL/kg, mean +/- SD).",Pharmacokinetics and pharmacodynamics of rocuronium (Org 9426) in elderly surgical patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8250312/),[ml] / [kg·min],5.03,240567,DB00728,Rocuronium
,8250312,volume of distribution,"Elderly patients, when compared with the younger, also exhibited a significant decrease in plasma clearance (3.67 +/- 1.0 vs 5.03 +/- 1.5 mL.kg-1.min-1, mean +/- SD) and volume of distribution (399 +/- 122 vs 553 +/- 279 mL/kg, mean +/- SD).",Pharmacokinetics and pharmacodynamics of rocuronium (Org 9426) in elderly surgical patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8250312/),[ml] / [kg],399,240568,DB00728,Rocuronium
,8250312,volume of distribution,"Elderly patients, when compared with the younger, also exhibited a significant decrease in plasma clearance (3.67 +/- 1.0 vs 5.03 +/- 1.5 mL.kg-1.min-1, mean +/- SD) and volume of distribution (399 +/- 122 vs 553 +/- 279 mL/kg, mean +/- SD).",Pharmacokinetics and pharmacodynamics of rocuronium (Org 9426) in elderly surgical patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8250312/),[ml] / [kg],553,240569,DB00728,Rocuronium
,14996264,T95,"The T95 values (+/-sd) for rocuronium were 110.1 +/- 39.3 s and 79.3 +/- 35.6 s for group 1 and group 2, respectively (P < 0.05).",The effect of environmental tobacco smoke on the dose requirements of rocuronium in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14996264/),s,110.1,244719,DB00728,Rocuronium
,14996264,T95,"The T95 values (+/-sd) for rocuronium were 110.1 +/- 39.3 s and 79.3 +/- 35.6 s for group 1 and group 2, respectively (P < 0.05).",The effect of environmental tobacco smoke on the dose requirements of rocuronium in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14996264/),s,79.3,244720,DB00728,Rocuronium
,14996264,T25,The T25 value of group 2 was 40.1 +/- 10.6 min and compared with group 1 values (30.85 +/- 7.02 min) it was significantly longer (P < 0.01).,The effect of environmental tobacco smoke on the dose requirements of rocuronium in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14996264/),min,40.1,244721,DB00728,Rocuronium
,14996264,T25,The T25 value of group 2 was 40.1 +/- 10.6 min and compared with group 1 values (30.85 +/- 7.02 min) it was significantly longer (P < 0.01).,The effect of environmental tobacco smoke on the dose requirements of rocuronium in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14996264/),min,30.85,244722,DB00728,Rocuronium
,8123396,Onset time for maximum block,"Onset time for maximum block, duration of clinical relaxation (T1(25)) and recovery index, were 61 (SD 25.0) s and 65 (16.4) s, 55 (26.9) min and 42 (9.3) min and 28 (12.3) min and 19 (8.8) min, respectively, for patients with and without renal failure.",Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8123396/),s,61,246879,DB00728,Rocuronium
,8123396,duration of clinical relaxation (T1(25)),"Onset time for maximum block, duration of clinical relaxation (T1(25)) and recovery index, were 61 (SD 25.0) s and 65 (16.4) s, 55 (26.9) min and 42 (9.3) min and 28 (12.3) min and 19 (8.8) min, respectively, for patients with and without renal failure.",Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8123396/),s,65,246880,DB00728,Rocuronium
,8123396,duration of clinical relaxation (T1(25)),"Onset time for maximum block, duration of clinical relaxation (T1(25)) and recovery index, were 61 (SD 25.0) s and 65 (16.4) s, 55 (26.9) min and 42 (9.3) min and 28 (12.3) min and 19 (8.8) min, respectively, for patients with and without renal failure.",Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8123396/),min,55,246881,DB00728,Rocuronium
,8123396,duration of clinical relaxation (T1(25)),"Onset time for maximum block, duration of clinical relaxation (T1(25)) and recovery index, were 61 (SD 25.0) s and 65 (16.4) s, 55 (26.9) min and 42 (9.3) min and 28 (12.3) min and 19 (8.8) min, respectively, for patients with and without renal failure.",Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8123396/),min,42,246882,DB00728,Rocuronium
,8123396,duration of clinical relaxation (T1(25)),"Onset time for maximum block, duration of clinical relaxation (T1(25)) and recovery index, were 61 (SD 25.0) s and 65 (16.4) s, 55 (26.9) min and 42 (9.3) min and 28 (12.3) min and 19 (8.8) min, respectively, for patients with and without renal failure.",Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8123396/),min,28,246883,DB00728,Rocuronium
,8123396,recovery index,"Onset time for maximum block, duration of clinical relaxation (T1(25)) and recovery index, were 61 (SD 25.0) s and 65 (16.4) s, 55 (26.9) min and 42 (9.3) min and 28 (12.3) min and 19 (8.8) min, respectively, for patients with and without renal failure.",Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8123396/),min,55,246884,DB00728,Rocuronium
,8123396,recovery index,"Onset time for maximum block, duration of clinical relaxation (T1(25)) and recovery index, were 61 (SD 25.0) s and 65 (16.4) s, 55 (26.9) min and 42 (9.3) min and 28 (12.3) min and 19 (8.8) min, respectively, for patients with and without renal failure.",Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8123396/),min,42,246885,DB00728,Rocuronium
,8123396,recovery index,"Onset time for maximum block, duration of clinical relaxation (T1(25)) and recovery index, were 61 (SD 25.0) s and 65 (16.4) s, 55 (26.9) min and 42 (9.3) min and 28 (12.3) min and 19 (8.8) min, respectively, for patients with and without renal failure.",Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8123396/),min,19,246886,DB00728,Rocuronium
,8123396,time for TOF ratio to,"The time for TOF ratio to return spontaneously to 0.7 was 99 (41.1) min and 73 (24.2) min, respectively, in the two groups.",Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8123396/),min,0,246887,DB00728,Rocuronium
,8123396,time for TOF ratio to,"The time for TOF ratio to return spontaneously to 0.7 was 99 (41.1) min and 73 (24.2) min, respectively, in the two groups.",Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8123396/),min,99,246888,DB00728,Rocuronium
,8123396,time for TOF ratio to,"The time for TOF ratio to return spontaneously to 0.7 was 99 (41.1) min and 73 (24.2) min, respectively, in the two groups.",Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8123396/),min,73,246889,DB00728,Rocuronium
,8123396,rates of clearance,"There were significant differences between patients with and without renal failure in the rates of clearance (2.5 (1.1) ml kg-1 min-1 and 3.7 (1.4) ml kg-1 min-1, respectively) and the mean residence times (97.1 (48.7) min and 58.3 (9.6) min) P < 0.05).",Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8123396/),[ml] / [kg·min],2.5,246890,DB00728,Rocuronium
,8123396,rates of clearance,"There were significant differences between patients with and without renal failure in the rates of clearance (2.5 (1.1) ml kg-1 min-1 and 3.7 (1.4) ml kg-1 min-1, respectively) and the mean residence times (97.1 (48.7) min and 58.3 (9.6) min) P < 0.05).",Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8123396/),[ml] / [kg·min],3.7,246891,DB00728,Rocuronium
,8123396,mean residence times,"There were significant differences between patients with and without renal failure in the rates of clearance (2.5 (1.1) ml kg-1 min-1 and 3.7 (1.4) ml kg-1 min-1, respectively) and the mean residence times (97.1 (48.7) min and 58.3 (9.6) min) P < 0.05).",Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8123396/),min,97.1,246892,DB00728,Rocuronium
,8123396,mean residence times,"There were significant differences between patients with and without renal failure in the rates of clearance (2.5 (1.1) ml kg-1 min-1 and 3.7 (1.4) ml kg-1 min-1, respectively) and the mean residence times (97.1 (48.7) min and 58.3 (9.6) min) P < 0.05).",Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8123396/),min,58.3,246893,DB00728,Rocuronium
,22584638,Time of onset,"Time of onset was significantly shorter for rocuronium than cisatracurium for the adult and elderly groups (P = 0.000), but the variability of cisatracurium was significantly greater compared with rocuronium for the same age groups (93.25 vs 37.01 s in the adult group and 64.56 vs 33.75 s in the elderly group; P = 0.000).",Comparison of the variability of the onset and recovery from neuromuscular blockade with cisatracurium versus rocuronium in elderly patients under total intravenous anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22584638/),s,93.25,250592,DB00728,Rocuronium
,22584638,Time of onset,"Time of onset was significantly shorter for rocuronium than cisatracurium for the adult and elderly groups (P = 0.000), but the variability of cisatracurium was significantly greater compared with rocuronium for the same age groups (93.25 vs 37.01 s in the adult group and 64.56 vs 33.75 s in the elderly group; P = 0.000).",Comparison of the variability of the onset and recovery from neuromuscular blockade with cisatracurium versus rocuronium in elderly patients under total intravenous anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22584638/),s,37.01,250593,DB00728,Rocuronium
,22584638,Time of onset,"Time of onset was significantly shorter for rocuronium than cisatracurium for the adult and elderly groups (P = 0.000), but the variability of cisatracurium was significantly greater compared with rocuronium for the same age groups (93.25 vs 37.01 s in the adult group and 64.56 vs 33.75 s in the elderly group; P = 0.000).",Comparison of the variability of the onset and recovery from neuromuscular blockade with cisatracurium versus rocuronium in elderly patients under total intravenous anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22584638/),s,64.56,250594,DB00728,Rocuronium
,22584638,Time of onset,"Time of onset was significantly shorter for rocuronium than cisatracurium for the adult and elderly groups (P = 0.000), but the variability of cisatracurium was significantly greater compared with rocuronium for the same age groups (93.25 vs 37.01 s in the adult group and 64.56 vs 33.75 s in the elderly group; P = 0.000).",Comparison of the variability of the onset and recovery from neuromuscular blockade with cisatracurium versus rocuronium in elderly patients under total intravenous anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22584638/),s,33.75,250595,DB00728,Rocuronium
,7893030,plasma clearance,"Hepatic impairment did not alter the plasma clearance of rocuronium (217 +/- 21.8 mL/min, mean +/- SE, for both groups), but did increase the volume of the central compartment (5.96 +/- 1.01 L for controls, 7.87 +/- 1.33 L for patients with liver disease) and volume of distribution at steady state (16.4 L for controls, 23.4 L for patients with liver disease).",The pharmacokinetics and neuromuscular effects of rocuronium bromide in patients with liver disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7893030/),[ml] / [min],217,252827,DB00728,Rocuronium
,7893030,volume of the central compartment,"Hepatic impairment did not alter the plasma clearance of rocuronium (217 +/- 21.8 mL/min, mean +/- SE, for both groups), but did increase the volume of the central compartment (5.96 +/- 1.01 L for controls, 7.87 +/- 1.33 L for patients with liver disease) and volume of distribution at steady state (16.4 L for controls, 23.4 L for patients with liver disease).",The pharmacokinetics and neuromuscular effects of rocuronium bromide in patients with liver disease. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7893030/),l,5.96,252828,DB00728,Rocuronium
,7893030,volume of the central compartment,"Hepatic impairment did not alter the plasma clearance of rocuronium (217 +/- 21.8 mL/min, mean +/- SE, for both groups), but did increase the volume of the central compartment (5.96 +/- 1.01 L for controls, 7.87 +/- 1.33 L for patients with liver disease) and volume of distribution at steady state (16.4 L for controls, 23.4 L for patients with liver disease).",The pharmacokinetics and neuromuscular effects of rocuronium bromide in patients with liver disease. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7893030/),l,7.87,252829,DB00728,Rocuronium
,7893030,volume of distribution at steady state,"Hepatic impairment did not alter the plasma clearance of rocuronium (217 +/- 21.8 mL/min, mean +/- SE, for both groups), but did increase the volume of the central compartment (5.96 +/- 1.01 L for controls, 7.87 +/- 1.33 L for patients with liver disease) and volume of distribution at steady state (16.4 L for controls, 23.4 L for patients with liver disease).",The pharmacokinetics and neuromuscular effects of rocuronium bromide in patients with liver disease. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7893030/),l,16.4,252830,DB00728,Rocuronium
,7893030,volume of distribution at steady state,"Hepatic impairment did not alter the plasma clearance of rocuronium (217 +/- 21.8 mL/min, mean +/- SE, for both groups), but did increase the volume of the central compartment (5.96 +/- 1.01 L for controls, 7.87 +/- 1.33 L for patients with liver disease) and volume of distribution at steady state (16.4 L for controls, 23.4 L for patients with liver disease).",The pharmacokinetics and neuromuscular effects of rocuronium bromide in patients with liver disease. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7893030/),l,23.4,252831,DB00728,Rocuronium
,7893030,elimination half-life,"In turn, elimination half-life was longer in patients with liver disease (111 min) compared to controls (75.4 min).",The pharmacokinetics and neuromuscular effects of rocuronium bromide in patients with liver disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7893030/),min,111,252832,DB00728,Rocuronium
,7893030,elimination half-life,"In turn, elimination half-life was longer in patients with liver disease (111 min) compared to controls (75.4 min).",The pharmacokinetics and neuromuscular effects of rocuronium bromide in patients with liver disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7893030/),min,75.4,252833,DB00728,Rocuronium
,16879519,Clearance,"Clearance was 3.91 +/- 2.07 and 3.62 +/- 0.80 ml x min(-1) x kg(-1) in sevoflurane and fentanyl groups, respectively (P < 0.65).",Pharmacokinetic-pharmacodynamic relationship of rocuronium under stable nitrous oxide-fentanyl or nitrous oxide-sevoflurane anesthesia in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16879519/),[ml] / [kg·min],3.91,252905,DB00728,Rocuronium
,16879519,Clearance,"Clearance was 3.91 +/- 2.07 and 3.62 +/- 0.80 ml x min(-1) x kg(-1) in sevoflurane and fentanyl groups, respectively (P < 0.65).",Pharmacokinetic-pharmacodynamic relationship of rocuronium under stable nitrous oxide-fentanyl or nitrous oxide-sevoflurane anesthesia in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16879519/),[ml] / [kg·min],3.62,252906,DB00728,Rocuronium
,16879519,Effect compartment concentrations corresponding,"Effect compartment concentrations corresponding to 50% inhibition of T1 (EC50) were 1.41 +/- 0.45 and 2.32 +/- 1.00 microg x ml(-1) (P < 0.02), and rate constants for equilibration between plasma and effect compartment (k(e0)) values were 0.10 +/- 0.04 and 0.24 +/- 0.14 min(-1) (P < 0.009) in sevoflurane and fentanyl groups, respectively.",Pharmacokinetic-pharmacodynamic relationship of rocuronium under stable nitrous oxide-fentanyl or nitrous oxide-sevoflurane anesthesia in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16879519/),[μg] / [ml],1.41,252907,DB00728,Rocuronium
,16879519,Effect compartment concentrations corresponding,"Effect compartment concentrations corresponding to 50% inhibition of T1 (EC50) were 1.41 +/- 0.45 and 2.32 +/- 1.00 microg x ml(-1) (P < 0.02), and rate constants for equilibration between plasma and effect compartment (k(e0)) values were 0.10 +/- 0.04 and 0.24 +/- 0.14 min(-1) (P < 0.009) in sevoflurane and fentanyl groups, respectively.",Pharmacokinetic-pharmacodynamic relationship of rocuronium under stable nitrous oxide-fentanyl or nitrous oxide-sevoflurane anesthesia in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16879519/),[μg] / [ml],2.32,252908,DB00728,Rocuronium
,16879519,rate constants,"Effect compartment concentrations corresponding to 50% inhibition of T1 (EC50) were 1.41 +/- 0.45 and 2.32 +/- 1.00 microg x ml(-1) (P < 0.02), and rate constants for equilibration between plasma and effect compartment (k(e0)) values were 0.10 +/- 0.04 and 0.24 +/- 0.14 min(-1) (P < 0.009) in sevoflurane and fentanyl groups, respectively.",Pharmacokinetic-pharmacodynamic relationship of rocuronium under stable nitrous oxide-fentanyl or nitrous oxide-sevoflurane anesthesia in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16879519/),1/[min],0.10,252909,DB00728,Rocuronium
,16879519,rate constants,"Effect compartment concentrations corresponding to 50% inhibition of T1 (EC50) were 1.41 +/- 0.45 and 2.32 +/- 1.00 microg x ml(-1) (P < 0.02), and rate constants for equilibration between plasma and effect compartment (k(e0)) values were 0.10 +/- 0.04 and 0.24 +/- 0.14 min(-1) (P < 0.009) in sevoflurane and fentanyl groups, respectively.",Pharmacokinetic-pharmacodynamic relationship of rocuronium under stable nitrous oxide-fentanyl or nitrous oxide-sevoflurane anesthesia in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16879519/),1/[min],0.24,252910,DB00728,Rocuronium
,24370612,AUC/dose,"The pharmacokinetic parameter estimations of ROC showed AUC/dose of 563 μg min/mL, total clearance of 2.5 mL/min/kg, volume of distribution at steady state of 190 mL/kg and mean residence time of 83 min.",Analysis of rocuronium in human plasma by liquid chromatography-tandem mass spectrometry with application in clinical pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24370612/),[min·μg] / [ml],563,257382,DB00728,Rocuronium
,24370612,total clearance,"The pharmacokinetic parameter estimations of ROC showed AUC/dose of 563 μg min/mL, total clearance of 2.5 mL/min/kg, volume of distribution at steady state of 190 mL/kg and mean residence time of 83 min.",Analysis of rocuronium in human plasma by liquid chromatography-tandem mass spectrometry with application in clinical pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24370612/),[ml] / [kg·min],2.5,257383,DB00728,Rocuronium
,24370612,volume of distribution at steady state,"The pharmacokinetic parameter estimations of ROC showed AUC/dose of 563 μg min/mL, total clearance of 2.5 mL/min/kg, volume of distribution at steady state of 190 mL/kg and mean residence time of 83 min.",Analysis of rocuronium in human plasma by liquid chromatography-tandem mass spectrometry with application in clinical pharmacokinetics. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24370612/),[ml] / [kg],190,257384,DB00728,Rocuronium
,24370612,mean residence time,"The pharmacokinetic parameter estimations of ROC showed AUC/dose of 563 μg min/mL, total clearance of 2.5 mL/min/kg, volume of distribution at steady state of 190 mL/kg and mean residence time of 83 min.",Analysis of rocuronium in human plasma by liquid chromatography-tandem mass spectrometry with application in clinical pharmacokinetics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24370612/),min,83,257385,DB00728,Rocuronium
,21034625,target plasma concentration (Cpt),"The beginning target plasma concentration (Cpt) was 2.0 µg/ml, then increased Cpt according to the neuromuscular transmission monitoring.",Population pharmacokinetics of rocuronium delivered by target-controlled infusion in adult patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21034625/),[μg] / [ml],2.0,257614,DB00728,Rocuronium
,21034625,clearance (CL)₁,"Pharmacokinetic parameters were clearance (CL)₁ = 0.205 L/min, CL₂ = 0.324 L/min, CL₃ = 0.0292 L/min, volumes of distribution (V)₁ = 4.00 L, V₂ = 2.28 L, V₃ = 4.26 L, Vdss = 10.54 L.",Population pharmacokinetics of rocuronium delivered by target-controlled infusion in adult patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21034625/),[l] / [min],0.205,257615,DB00728,Rocuronium
,21034625,CL₂,"Pharmacokinetic parameters were clearance (CL)₁ = 0.205 L/min, CL₂ = 0.324 L/min, CL₃ = 0.0292 L/min, volumes of distribution (V)₁ = 4.00 L, V₂ = 2.28 L, V₃ = 4.26 L, Vdss = 10.54 L.",Population pharmacokinetics of rocuronium delivered by target-controlled infusion in adult patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21034625/),[l] / [min],0.324,257616,DB00728,Rocuronium
,21034625,CL₃,"Pharmacokinetic parameters were clearance (CL)₁ = 0.205 L/min, CL₂ = 0.324 L/min, CL₃ = 0.0292 L/min, volumes of distribution (V)₁ = 4.00 L, V₂ = 2.28 L, V₃ = 4.26 L, Vdss = 10.54 L.",Population pharmacokinetics of rocuronium delivered by target-controlled infusion in adult patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21034625/),[l] / [min],0.0292,257617,DB00728,Rocuronium
,21034625,volumes of distribution (V)₁,"Pharmacokinetic parameters were clearance (CL)₁ = 0.205 L/min, CL₂ = 0.324 L/min, CL₃ = 0.0292 L/min, volumes of distribution (V)₁ = 4.00 L, V₂ = 2.28 L, V₃ = 4.26 L, Vdss = 10.54 L.",Population pharmacokinetics of rocuronium delivered by target-controlled infusion in adult patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21034625/),l,4.00,257618,DB00728,Rocuronium
,21034625,V₂,"Pharmacokinetic parameters were clearance (CL)₁ = 0.205 L/min, CL₂ = 0.324 L/min, CL₃ = 0.0292 L/min, volumes of distribution (V)₁ = 4.00 L, V₂ = 2.28 L, V₃ = 4.26 L, Vdss = 10.54 L.",Population pharmacokinetics of rocuronium delivered by target-controlled infusion in adult patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21034625/),l,2.28,257619,DB00728,Rocuronium
,21034625,V₃,"Pharmacokinetic parameters were clearance (CL)₁ = 0.205 L/min, CL₂ = 0.324 L/min, CL₃ = 0.0292 L/min, volumes of distribution (V)₁ = 4.00 L, V₂ = 2.28 L, V₃ = 4.26 L, Vdss = 10.54 L.",Population pharmacokinetics of rocuronium delivered by target-controlled infusion in adult patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21034625/),l,4.26,257620,DB00728,Rocuronium
,21034625,Vdss,"Pharmacokinetic parameters were clearance (CL)₁ = 0.205 L/min, CL₂ = 0.324 L/min, CL₃ = 0.0292 L/min, volumes of distribution (V)₁ = 4.00 L, V₂ = 2.28 L, V₃ = 4.26 L, Vdss = 10.54 L.",Population pharmacokinetics of rocuronium delivered by target-controlled infusion in adult patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21034625/),l,10.54,257621,DB00728,Rocuronium
,9278198,25% recovery T1:T0,"The mean (s.d.) recovery times were prolonged in the cirrhotic compared with the healthy group: 25% recovery T1:T0, 53.7 (18.1) vs 42.3 (14.2) min; 50% recovery T1:T0, 73.9 (33.9) vs 52.6 (19.8) min; 75% recovery T1:T0, 84.2 (24.5) vs 66.8 (27.2) min (all P<0.05); recovery of T4:T1 to 70%, 114.9 (31.7) vs 76.1 (28.8) min (P<0.01).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,53.7,258187,DB00728,Rocuronium
,9278198,25% recovery T1:T0,"The mean (s.d.) recovery times were prolonged in the cirrhotic compared with the healthy group: 25% recovery T1:T0, 53.7 (18.1) vs 42.3 (14.2) min; 50% recovery T1:T0, 73.9 (33.9) vs 52.6 (19.8) min; 75% recovery T1:T0, 84.2 (24.5) vs 66.8 (27.2) min (all P<0.05); recovery of T4:T1 to 70%, 114.9 (31.7) vs 76.1 (28.8) min (P<0.01).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,42.3,258188,DB00728,Rocuronium
,9278198,50% recovery T1:T0,"The mean (s.d.) recovery times were prolonged in the cirrhotic compared with the healthy group: 25% recovery T1:T0, 53.7 (18.1) vs 42.3 (14.2) min; 50% recovery T1:T0, 73.9 (33.9) vs 52.6 (19.8) min; 75% recovery T1:T0, 84.2 (24.5) vs 66.8 (27.2) min (all P<0.05); recovery of T4:T1 to 70%, 114.9 (31.7) vs 76.1 (28.8) min (P<0.01).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,73.9,258189,DB00728,Rocuronium
,9278198,50% recovery T1:T0,"The mean (s.d.) recovery times were prolonged in the cirrhotic compared with the healthy group: 25% recovery T1:T0, 53.7 (18.1) vs 42.3 (14.2) min; 50% recovery T1:T0, 73.9 (33.9) vs 52.6 (19.8) min; 75% recovery T1:T0, 84.2 (24.5) vs 66.8 (27.2) min (all P<0.05); recovery of T4:T1 to 70%, 114.9 (31.7) vs 76.1 (28.8) min (P<0.01).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,52.6,258190,DB00728,Rocuronium
,9278198,75% recovery,"The mean (s.d.) recovery times were prolonged in the cirrhotic compared with the healthy group: 25% recovery T1:T0, 53.7 (18.1) vs 42.3 (14.2) min; 50% recovery T1:T0, 73.9 (33.9) vs 52.6 (19.8) min; 75% recovery T1:T0, 84.2 (24.5) vs 66.8 (27.2) min (all P<0.05); recovery of T4:T1 to 70%, 114.9 (31.7) vs 76.1 (28.8) min (P<0.01).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,84.2,258191,DB00728,Rocuronium
,9278198,T1:T0,"The mean (s.d.) recovery times were prolonged in the cirrhotic compared with the healthy group: 25% recovery T1:T0, 53.7 (18.1) vs 42.3 (14.2) min; 50% recovery T1:T0, 73.9 (33.9) vs 52.6 (19.8) min; 75% recovery T1:T0, 84.2 (24.5) vs 66.8 (27.2) min (all P<0.05); recovery of T4:T1 to 70%, 114.9 (31.7) vs 76.1 (28.8) min (P<0.01).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,84.2,258192,DB00728,Rocuronium
,9278198,T1:T0,"The mean (s.d.) recovery times were prolonged in the cirrhotic compared with the healthy group: 25% recovery T1:T0, 53.7 (18.1) vs 42.3 (14.2) min; 50% recovery T1:T0, 73.9 (33.9) vs 52.6 (19.8) min; 75% recovery T1:T0, 84.2 (24.5) vs 66.8 (27.2) min (all P<0.05); recovery of T4:T1 to 70%, 114.9 (31.7) vs 76.1 (28.8) min (P<0.01).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,66.8,258193,DB00728,Rocuronium
,9278198,recovery of T4:T1,"The mean (s.d.) recovery times were prolonged in the cirrhotic compared with the healthy group: 25% recovery T1:T0, 53.7 (18.1) vs 42.3 (14.2) min; 50% recovery T1:T0, 73.9 (33.9) vs 52.6 (19.8) min; 75% recovery T1:T0, 84.2 (24.5) vs 66.8 (27.2) min (all P<0.05); recovery of T4:T1 to 70%, 114.9 (31.7) vs 76.1 (28.8) min (P<0.01).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,114.9,258194,DB00728,Rocuronium
,9278198,recovery of T4:T1,"The mean (s.d.) recovery times were prolonged in the cirrhotic compared with the healthy group: 25% recovery T1:T0, 53.7 (18.1) vs 42.3 (14.2) min; 50% recovery T1:T0, 73.9 (33.9) vs 52.6 (19.8) min; 75% recovery T1:T0, 84.2 (24.5) vs 66.8 (27.2) min (all P<0.05); recovery of T4:T1 to 70%, 114.9 (31.7) vs 76.1 (28.8) min (P<0.01).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,76.1,258195,DB00728,Rocuronium
,9278198,Plasma clearance,Plasma clearance was significantly reduced in the cirrhotic group (2.66 (0.60) vs 3.70 (1.03) ml kg(-1) min (-1); P<0.005).,The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),[-1·min·ml] / [kg],2.66,258196,DB00728,Rocuronium
,9278198,Plasma clearance,Plasma clearance was significantly reduced in the cirrhotic group (2.66 (0.60) vs 3.70 (1.03) ml kg(-1) min (-1); P<0.005).,The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),[-1·min·ml] / [kg],3.70,258197,DB00728,Rocuronium
,9278198,redistribution (,"The slow redistribution (t1/2,lambda1) and elimination (t1/2,z) half-lives were both significantly prolonged in cirrhosis (28.3 (12.1) vs 16.8 (4.6) min, P < 0.005; and 143 (80) vs 92 (40) min, P < 0.05 respectively).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,28.3,258198,DB00728,Rocuronium
,9278198,"t1/2,lambda1","The slow redistribution (t1/2,lambda1) and elimination (t1/2,z) half-lives were both significantly prolonged in cirrhosis (28.3 (12.1) vs 16.8 (4.6) min, P < 0.005; and 143 (80) vs 92 (40) min, P < 0.05 respectively).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,28.3,258199,DB00728,Rocuronium
,9278198,"elimination (t1/2,z) half-lives","The slow redistribution (t1/2,lambda1) and elimination (t1/2,z) half-lives were both significantly prolonged in cirrhosis (28.3 (12.1) vs 16.8 (4.6) min, P < 0.005; and 143 (80) vs 92 (40) min, P < 0.05 respectively).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,16.8,258200,DB00728,Rocuronium
,9278198,"elimination (t1/2,z) half-lives","The slow redistribution (t1/2,lambda1) and elimination (t1/2,z) half-lives were both significantly prolonged in cirrhosis (28.3 (12.1) vs 16.8 (4.6) min, P < 0.005; and 143 (80) vs 92 (40) min, P < 0.05 respectively).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,143,258201,DB00728,Rocuronium
,9278198,"elimination (t1/2,z) half-lives","The slow redistribution (t1/2,lambda1) and elimination (t1/2,z) half-lives were both significantly prolonged in cirrhosis (28.3 (12.1) vs 16.8 (4.6) min, P < 0.005; and 143 (80) vs 92 (40) min, P < 0.05 respectively).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,92,258202,DB00728,Rocuronium
,9278198,exit rate constant for,"The exit rate constant for the effect compartment k(eo) was significantly increased in the cirrhotic group (0.25 (0.18) vs 0.16 (0.06) min(-1); P < 0.05), but cirrhosis had no significant effect on the parameters of the concentration-effect relationship Cp(ss)(50) and gamma.",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),1/[min],0.25,258203,DB00728,Rocuronium
,9278198,exit rate constant for,"The exit rate constant for the effect compartment k(eo) was significantly increased in the cirrhotic group (0.25 (0.18) vs 0.16 (0.06) min(-1); P < 0.05), but cirrhosis had no significant effect on the parameters of the concentration-effect relationship Cp(ss)(50) and gamma.",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),1/[min],0.16,258204,DB00728,Rocuronium
,11417864,extraction efficiency,The extraction efficiency was approximately 75% for rocuronium and approximately 50% for 17-desacetylrocuronium.,"Gas chromatographic-mass spectrometric assay for rocuronium with potential for quantifying its metabolite, 17-desacetylrocuronium, in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11417864/),%,75,260228,DB00728,Rocuronium
,11417864,extraction efficiency,The extraction efficiency was approximately 75% for rocuronium and approximately 50% for 17-desacetylrocuronium.,"Gas chromatographic-mass spectrometric assay for rocuronium with potential for quantifying its metabolite, 17-desacetylrocuronium, in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11417864/),%,50,260229,DB00728,Rocuronium
,11927473,clinical duration,"After the second bolus, clinical duration was 20 +/- 6 min in the propofol group vs 39 +/- 8 min in the isoflurane group (P <0.05).",Rocuronium pharmacokinetic-pharmacodynamic relationship under stable propofol or isoflurane anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11927473/),min,20,260546,DB00728,Rocuronium
,11927473,clinical duration,"After the second bolus, clinical duration was 20 +/- 6 min in the propofol group vs 39 +/- 8 min in the isoflurane group (P <0.05).",Rocuronium pharmacokinetic-pharmacodynamic relationship under stable propofol or isoflurane anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11927473/),min,39,260547,DB00728,Rocuronium
,11927473,effect compartment concentration corresponding to 50,"The effect compartment concentration corresponding to 50% block, EC50, was higher under propofol anesthesia: 1008 vs 592 microg x L(-1) (P <0.05).",Rocuronium pharmacokinetic-pharmacodynamic relationship under stable propofol or isoflurane anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11927473/),[μg] / [l],1008,260548,DB00728,Rocuronium
,11927473,effect compartment concentration corresponding to 50,"The effect compartment concentration corresponding to 50% block, EC50, was higher under propofol anesthesia: 1008 vs 592 microg x L(-1) (P <0.05).",Rocuronium pharmacokinetic-pharmacodynamic relationship under stable propofol or isoflurane anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11927473/),[μg] / [l],592,260549,DB00728,Rocuronium
,11927473,EC50,"The effect compartment concentration corresponding to 50% block, EC50, was higher under propofol anesthesia: 1008 vs 592 microg x L(-1) (P <0.05).",Rocuronium pharmacokinetic-pharmacodynamic relationship under stable propofol or isoflurane anesthesia. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11927473/),[μg] / [l],1008,260550,DB00728,Rocuronium
,11927473,EC50,"The effect compartment concentration corresponding to 50% block, EC50, was higher under propofol anesthesia: 1008 vs 592 microg x L(-1) (P <0.05).",Rocuronium pharmacokinetic-pharmacodynamic relationship under stable propofol or isoflurane anesthesia. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11927473/),[μg] / [l],592,260551,DB00728,Rocuronium
,20077775,time to spontaneous recovery,"The time to spontaneous recovery with a twitch height of 25% and a reappearance of the fourth response in train-of-four ratio (TOF ratio) nerve stimulation was twenty minutes, even after a five-hour infusion, and was not affected by the length of the infusion.",[Estimated blood concentration of rocuronium administrated by continuous infusion to maintain an appropriate neuromuscular blockade under propofol anesthesia]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20077775/),min,twenty,264946,DB00728,Rocuronium
,16571960,median recovery time,Sugammadex decreased median recovery time in a dose-dependent manner from 21.0 min in the placebo group to 1.1 min in the group receiving 4.0 mg/kg sugammadex.,Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16571960/),min,21.0,266635,DB00728,Rocuronium
,16571960,median recovery time,Sugammadex decreased median recovery time in a dose-dependent manner from 21.0 min in the placebo group to 1.1 min in the group receiving 4.0 mg/kg sugammadex.,Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16571960/),min,1.1,266636,DB00728,Rocuronium
,22732111,clearance,"On average, dialysis clearance of sugammadex and rocuronium in blood was 78 and 89 ml min(-1), respectively.",Dialysability of sugammadex and its complex with rocuronium in intensive care patients with severe renal impairment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22732111/),[ml] / [min],78,267596,DB00728,Rocuronium
,22732111,clearance,"On average, dialysis clearance of sugammadex and rocuronium in blood was 78 and 89 ml min(-1), respectively.",Dialysability of sugammadex and its complex with rocuronium in intensive care patients with severe renal impairment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22732111/),[ml] / [min],89,267597,DB00728,Rocuronium
